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Quantum dots are semiconductor nanocrystals with size-dependent optical properties 
that result from their nanoscale dimensions. These materials are emerging as simpler 
and more sensitive alternatives to traditional fluorescent small molecules and 
radioactive reporters in biomarker assays. Quantum dot emission can be modulated 
via proximal binding of organic dyes or gold nanoparticles, which can form the basis 
of a sensor. Their multivalency and ease of functionalisation allow for the attachment 
of multiple biosensing ligands, boosting the detection sensitivity. Quantum dots with 
different emission wavelengths can be excited simultaneously and distinguished from 
one another spectrally, a property which can be used for multiplexing. 
Enzymes mediate the chemical modification of proteins thereby controlling the 
signalling cascades that regulate cell behaviour. Hence, aberrant activity of enzymes 
can be associated with the onset of disease. Clinical tests typically determine the total 
concentration of enzyme in a sample without regard to quantification of activity. In 
this thesis, the development of generic activity-dependent tests for acetyltransferases, 
kinases and proteases is described.  
Enzyme activity is reported via decoration of quantum dots with enzyme substrate 
peptides and subsequent binding of FRET acceptor dye-labelled antibodies, which 
mediate changes in quantum dot emission spectra. Using this platform, p300 histone 
acetyltransferase was detected with a limit of detection comparable to that of 
radiolabelling assays. Modifications of the platform to detect serine and tyrosine 
phosphorylation were investigated. The phosphotyrosine assay was combined with a 
gold nanoparticle-quantum dot assay for the detection of a kinase/protease biomarker 
pair relevant for the determination of breast cancer prognosis. The modular nature of 
this assay design allowed for the detection of different classes of enzymes singly and 
simultaneously, representing a generic platform for high-throughput enzyme 
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The philosopher and statesman Sir Francis Bacon wrote: “for knowledge, too, is itself 
power”, an aphorism that encompasses humanity’s urge to discover, but also to effect 
change. Nowhere is this more true than in the life sciences, where the knowledge 
gained through research can be put into practical use for improving the health and 
wellbeing of the human population. As a result of medical and technical advances in 
the past 100 years, the world population has grown from less than 2 billion in 1912 to 
over 7 billion today. Not only are there more people alive but they are also living 
longer, and age-related diseases such as cancer are now a pressing problem in the 
developed world. On the other side of the coin, the developing world’s population 
boom has resulted in a predominantly youthful society. The economic development of 
these countries depends on these children remaining healthy and productive into 
working age. Hence, there is also a strong focus on tropical diseases such as malaria 
and HIV/AIDS, which have the potential to decimate these populations.  
Research into these diseases, accurate and timely diagnosis, and discovery of new 
drugs all require means of monitoring and detecting biomolecular clues. New sensing 
methodologies are providing a wealth of information about disease phenotypes. 
Within this paradigm, rapid and sensitive detection is a must. Developments in this 
area will help improve patient outcomes and reduce the burden of disease. In cancer, 
tumours are often discovered only after they have reached an advanced stage of 
progression, increasing the probability that the cancer has metastasized to other 
organs. Hence, the accurate diagnosis of cancer in its earliest stages is of extreme 
clinical importance. Indeed, the UK and WHO have both recognised early tumour 
diagnosis as a key priority [1, 2]. The ongoing battle against drug resistance in 
infectious disease means that there is a constant search for new drugs and also new 
drug targets. Proteomics research promises to elucidate many of the interactions 
present in the body that cause disease. Using this information, screens for new 
molecules that hinder disadvantageous interactions can be performed. Another 
exciting development is the assessment of patient health via biomarker profiling or 
‘fingerprinting’. Here, the focus is on the increase in predictive power gained by 
quantifying multiple markers.  
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Alongside the increasing need for information at the molecular level lie several 
drawbacks experienced by traditional sensing methods, including: a lack of 
sensitivity; poor reproducibility; and cumbersome sample preparation. Many of the 
state of the art assays utilise fluorescent organic molecules, which can be unstable 
under repeated photoexcitation (photobleaching) and possess wide emission spectra, 
precluding their use in multiple-target assays. In the past 30 years, scientists have 
developed materials with nanoscale dimensions that exhibit quantum effects and 
novel physical properties not present in the bulk material. In terms of sensing, 
phenomena that have been exploited include: super-paramagnetism; surface plasmon 
resonance; and quantised fluorescence emission. These properties are often size- and 
material-dependent, offering researchers a wide palette for designing sensing 
strategies which enhance signals, whilst avoiding large background effects. 
Nanoparticle (NP)-based sensors promise to add another weapon to the arsenal of 
detection strategies. 
This thesis focuses on quantum dot (QD)-based detection strategies, which have 
begun to attract considerable interest due to the strong and narrow emission properties 
of QDs. In the medical field, QDs have the potential to be used as imaging and 
sensing agents [3], which is a strong motivation for pursuing this line of research. The 
detection systems described herein are highly generic, with applications envisaged 
ranging from basic scientific research, to early diagnosis of disease, to high-
throughput screening (HTS) for drug discovery. 
 
1.1.1 Scope of the thesis 
This thesis concerns the development of activity-dependent enzyme detection 
systems, based on the nanoscale and optical properties of semiconductor QDs. Using 
generic design principles, and a toolbox consisting of: QDs with different emission 
wavelengths; synthetic peptides; monoclonal antibodies; and organic dyes/gold 
nanoparticles (Au NPs) to modulate the QD emission, detection systems for histone 
acetyltransferases, kinases, and proteases have been demonstrated. The QDs present a 
large ensemble surface area for attachment of sensing ligands, enhancing signal at low 
analyte concentrations. The variety of biofunctionalisation strategies and the 
possibility to excite multiple emission wavelengths with a common source opens up 
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new sensing modalities, including simultaneous detection of multiple analytes 
(multiplexing). 
The Introduction chapter covers the theoretical background behind molecular 
fluorescence, focusing on the origins of QD emission due to quantisation of optical 
properties at the nanoscale, and explaining the basis by which the QD emission is 
modified in the presence of organic dyes (Förster Resonance Energy Transfer, FRET) 
and Au NPs (quenching). The biological significance of the enzyme targets and 
clinical motivation behind biomolecular sensing is discussed in Section 1.3. To 
complete the introduction, a review of established (non-NP-based) and new (including 
NP-based strategies) biosensing assays is presented, to provide a context for the 
remainder of the thesis. The following Chapters 2 and 3 focus on single-target assays, 
whereas Chapter 4 describes the development of a multiple-target assay.  
In Chapter 2, attempts to re-engineer an existing platform for kinase detection for the 
detection of acetyltransferase activity are described. The major modifications required 
were the use of HAT-specific substrate peptides derived from histone tail domains, 
and sensing the acetylation with anti-acetyl specific antibodies. The response of the 
assay in the presence of enzyme inhibitors was also tested, validating the utility of this 
approach for drug screening applications. This chapter demonstrates the main 
concepts and design principles behind all the enzyme assays in this thesis. In Chapter 
3, modifications to the assay design were considered in order to explore alternative 
sensing options, other than antibodies. This investigation would increase the 
applicability of this assay platform to targets for which no specific antibody exists. 
Chapter 4 applies the principles outlined in the preceding chapters to the detection of 
human epidermal growth factor receptor 2 (HER2) tyrosine kinase, and introduces a 
detection modality for urokinase-type plasminogen activator (uPA) protease (this 
biomarker pair is indicative of prognosis in breast cancer). These two assays were 
subsequently combined into a homogeneous system for the multiplexed detection of 
the two enzyme targets. Finally, some general remarks about the applicability of QD-
based assays in a range of settings are presented in Chapter 5, along with a 
perspective on possible future directions. 
By demonstrating QD-based sensing in a range of formats, the general applicability of 
the format can be appreciated. This work fits well with the existing literature on 




1.2 Optically active materials 
Detectors for any type of analyte require a mechanism for transduction of the signal. 
One class of signal is optical, where an analyte induces a change in the emission or 
absorption properties of the detector, typically measured via spectroscopy. 
 
1.2.1 Fluorescent materials 
Fluorescent materials are those which, when irradiated with light of a specific 
wavelength, re-emit photons at wavelengths dependent on the electronic states in the 
material, typically after a delay of a few ns. 
Figure 1 shows the principles of fluorescence. Transitions between energy levels can 
be induced by absorption of a photon of sufficient energy, and subsequent de- 
 
Figure 1. Principles of molecular fluorescence. Incident radiation excites molecular 
transitions, which then relax to a radiative excited state. The excited state decays to 




Figure 2. Examples of fluorescent dyes, molecular structures, and optical properties. 
Molecular structures adapted from Sapsford et al. Excitation and emission data 
provided by Invitrogen (Life Technologies, Inc.). 
excitation is accompanied by emission of a photon of specific energy corresponding 
to the gap between the excited state and the ground state. Electronic state transitions 
within molecules can be probed by illumination with ultraviolet (UV) radiation, and 
monitoring of the emission of longer-wavelength photons. 
Organic molecules that exhibit fluorescence typically contain multiple aromatic 
groups that generate well-defined electronic states arising from the interactions 
between molecular orbitals. Examples of organic dye molecules are given in 
publications by Sapsford et al. [4] and Lakowicz [5] and are illustrated in Figure 2, 
along with the wavelengths of maximum excitation and emission intensity for each 
molecule. Figure 3 shows the absorption and emission spectra for the AlexaFluor 660 
(AF660) dye. A number of features may be observed; firstly, that the dye absorption 
and emission spectra have a finite width and are asymmetrical; secondly, the spectra 
appear to be reflections of each other; and finally, the peaks are separated, by an 
amount known as the Stokes shift. The width of the spectra is due to the vibrational 
motion of the molecule, a result of which is that there exist a number of vibrational 
energy states associated with each excited state. Electrons can be excited into these 
states (labelled S1 in Figure 1) by incident radiation, hence broadening the absorption 




Figure 3. Absorption (left) and emission (right) spectra of AlexaFluor 660 dye. 
reflected spectra can also be explained; this is because the molecular vibrational states 
are not influenced by the electron transitions, hence the same range of states may be 
accessed in excitation and de-excitation. The Stokes shift arises due to rapid thermal 
relaxation of the vibrational states, on a timescale much shorter than the lifetime of 
the electronic excited states (‘internal relaxation’ in Figure 1). For this reason, the de-
excitation almost always occurs from the lowest vibrational energy state, at lower 
energy (longer emission wavelength) than the excitation. 
 
1.2.1.1 Fluorescence spectroscopy 
The instrumentation for collecting fluorescence emission data requires an excitation 
source, and a detector to measure the emission intensity at specified wavelengths. The 
excitation source can take the form of a laser with a known emission wavelength, or 
alternatively a source emitting across a broad wavelength range can be used. In the 
second case, optical filters and monochromator gratings are necessary to select the 
desired excitation wavelength. This set-up is known as a spectrofluorimeter, and 
affords greater flexibility in selection of excitation wavelengths. Common sources of 
background intensity include stray light from the excitation source, and biological 
sources of fluorescence, such as aromatic amino acid residues.  
For the purposes of this thesis, spectra were read in the spectrophotometer mode using 
a SpectraMax M5 microplate reader (Molecular Devices, Wokingham, UK). 
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1.2.2 Quantum Dots 
QDs are semiconductor NPs. The material properties of semiconductors are defined 
by the density of states occupied by electrons and holes. In the bulk, semiconductor 
conduction and valence bands have a continuous density of states, whereas confining 
electrons to the nanoscale alters the density of states at the band edges and results in a 
quantised density of states.  
In a semiconductor, the allowed electron energy levels are given by Equation 1:  
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    (1) 
where 
E = energy of the electronic state 
Eg = band gap between bonding and antibonding electron states 
nx, ny, nz = integers corresponding to allowed quantum states 
me = effective mass of the electron in the semiconductor 
Lx, Ly, Lz = dimensions of the semiconductor crystal. 
 
Figure 4. Semiconductor electronic band structure for bulk materials (left) and 
nanomaterials (right). Electron energies within the crystal lattice are plotted against 
the density of states at each energy. Left – in the bulk, the density of states is 
continuous right up to the unoccupied/occupied band gap edges. Right – in 
nanoparticles, the energy levels are quantised at the band edges, leading to discrete 
steps between energy levels and a size-dependent band gap. 
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Figure 4 illustrates the allowed electronic states of a semiconductor in both the bulk 
and nanoparticle forms. In a bulk semiconductor, the transition energy between the 
lowest unoccupied state and the highest occupied state (band gap) is fixed because 
electronic states exist right down to the band edges. However, at the nanoscale, 
electronic states are constrained by Equation 1 and hence the transition energy is 
dependent on the size of the NP (Lx, Ly, Lz). In a semiconductor NP, an incident 
photon of sufficient energy can create an electron-hole pair (exciton), which 
recombines at the band edge, emitting a photon of specific energy, which is the origin 
of the size-and material-dependent emission spectra of QDs. 
 
1.2.2.1 Synthesis and optical properties of QDs 
Many of the features of the optical properties of QDs can be understood by 
considering their synthesis, as described by Murray et al. [6] and Hines et al. [7]. For 
the preparation of CdSe QDs in organic solvent [6], tri-n-octylphosphine (TOP), tri-n-
octylphosphine oxide (TOPO), dimethylcadmium and trioctylphosphine selenide are 
mixed in an inert atmosphere at 300 °C. The TOP/TOPO acts as a solvent for the 
growth and annealing of CdSe NPs, and also passivates the surface electrostatically 
preventing NP aggregation. Following the initial nucleation of the NPs, the final QD 
radius (and emission wavelength) is increased by lengthening the reaction time. It is 
possible to prepare highly monodisperse QD samples by this method, with the 
corresponding absorption and emission spectra shown in Figure 5. 
By contrast with the AF660 spectra shown in Figure 3, the CdSe QDs exhibit a 
narrower emission spectrum, not only in terms of full width at half-maximum 
(FWHM), but also in terms of the asymmetric tail at long wavelengths, which is much 
less pronounced for the QDs. The most marked difference, however, is in the 
absorption spectrum. Due to the electronic band structure of the QDs, the absorption 
extends well into the UV range, and in fact, the absorption coefficient is much 
amplified at shorter wavelengths. It is this feature that makes the QDs attractive FRET 
donors; it is easy to excite the QDs at a wavelength far from the excitation band of the 
acceptor molecule (see Section 1.2.3 for a discussion of FRET).  
After the initial study of Murray et al. [6], improvement of the quantum yield (QY) 
was achieved by growing a ZnS shell around the CdSe QDs [7]. The ZnS shell 




Figure 5. Absorption (left) and emission (right) spectra of CdSe/ZnS QDs with a 
nominal emission wavelength of 655 nm (QD655) after transfer from decane into 
borate buffer, pH 9.6. 
– the band gap of ZnS is larger than that of CdSe, and so holes and electrons are 
confined to the CdSe core. This prevents so-called ‘trapping’ in low energy surface 
states, which provide a route for non-radiative transitions to the ground state. 
 
1.2.2.2 Behaviour of QDs in aqueous solvents 
QDs possess numerous advantages over traditional fluorescent dyes for biological 
applications [8]. They have bright, narrow emission spectra, which is of great 
importance in the development of high-sensitivity detection systems. The peak 
emission wavelength of QDs is tightly controlled by the core size (as discussed in 
Section 1.2.2), and materials scientists have designed QDs with emission maxima 
encompassing the entire visible spectrum and even into the UV and infra-red (IR) [9]. 
It is also possible to excite QDs at wavelengths far removed from the emission peak, 
reducing effects such as spectral bleed from the excitation source, or direct excitation 
of FRET acceptors (whose absorption bands may overlap those of the donor 
molecule). Finally, the nanoscale dimensions and readily-accessible surface chemistry 
of QDs affords the potential for significant signal amplification by attachment of 
multiple ligands to the QD surface. In fact, QD functionalisation can be realised via a 
27 
 
wide array of coupling chemistries, many of which can be accessed with self-
assembly strategies [10], for example dative thiol bond formation; hydrophobic 
interactions burying nonpolar moieties; and His tag-metal affinity coordination 
(several consecutive histidine residues, most commonly six in a row, is known as a 
His tag [11]). The ease of QD surface decoration allows for the option of analyte-
target interactions to be carried out in the absence of the NPs (more realistically 
simulating the native biological interaction) before introduction of the QDs as reporter 
molecules.  
These advantages became pertinent to the biological community once it had been 
shown that QDs could be stabilised in aqueous solvents, whilst still retaining their 
emission properties [12, 13]. A commonly-used method of rendering CdSe/ZnS QDs 
soluble in water is by replacing the hydrophobic TOP/TOPO capping layer with a 
heterobifunctional ligand containing a hydrophilic motif and a QD-binding motif (for 
a study on the use of 3-mercaptopropionic acid (MPA), see Pong et al. [14]). 
Although these methods have been quite successful in preparing QDs with impressive 
optical properties, it has been observed that the QD emission is often affected by 
changes in the surface layer [15], perhaps due to exposure of surface defects that can 
trap holes and prevent exciton recombination [16]. 
 
1.2.3 FRET 
FRET was described theoretically by Theodor Förster [17] and describes the distance-
dependent, non-radiative transfer of energy between the excited states of neighbouring 
fluorescent molecules. FRET is only applicable to molecules containing electronic 
transitions of similar energy, whereby an excited (donor) molecule can transfer its 
energy (via a dipole-dipole interaction), inducing an excited state in an acceptor 
molecule. The strength of dipole-dipole interactions is modulated by an r-6 
dependence, and so the rate of energy transfer kT(r) can be written as: 
 = 	 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         (2) 
where: 
r = donor-acceptor separation distance 
τD = fluorescence lifetime of the donor in the absence of the acceptor 
R0 = Förster radius (separation at which the rate of donor radiative emission is 
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matched by the rate of FRET). 
The FRET efficiency, EF, is defined as the proportion of photons absorbed by the 
donor which contribute to FRET. Summing the rates of donor de-excitation to 
determine the total number of photons involved yields: 
E% =	 &'"&'"()*=	

("  !⁄ ,        (3) 
where Equation 2 has been substituted to give a relation in terms of r and R0. 
In terms of fluorescence intensity, 
EF		=	 ./.DA.D 	          (4) 
where: 
ID = peak fluorescence intensity of the donor alone 
IDA = peak fluorescence intensity of the donor in the presence of the acceptor. 
R0 can be calculated from the optical properties of the system and overlap between the 
emission spectrum of the donor and the absorbance spectrum of the acceptor using 
Equation 5 [5]. 
23	4Å6 = 	0.211;<=/>QD @ FDλ ∙ εAλ ∙ λ>DλE3 F #⁄     (5) 
where 
κ = dipole orientation factor (κ2 assumed to be 2/3 for randomly oriented molecules)  
n = refractive index of the medium  
QD = QY of the donor molecule 
FD(λ) = normalized emission spectrum of the donor molecule 
εA(λ) = wavelength-dependent extinction coefficient of the acceptor molecule.  
(wavelengths measured in nm).  
R0 was calculated by Nikiforov et al. [18] for a number of QD-AF dye donor-acceptor 
pairs; these are listed in Table 1.  
 
 AlexaFluor 594 AlexaFluor 647 AlexaFluor 680 
QD565 60.9 54.1 55.2 
QD605 n. a. 71.5 67.5 
QD655 n .a. n. a. 84.0 
Table 1. Calculated Förster radii, R0 (in Å), between QDs emitting at 565, 605, and 
655 nm, and the AlexaFluor dyes with absorbance maxima at 594, 647, and 680 nm. 






Figure 6. FRET efficiency for a donor molecule surrounded by m acceptors, each at 
the same distance from the donor. The FRET response is plotted for different donor-
acceptor distances, represented by differently coloured data points. 
The FRET systems described in this thesis involve the assembly of multiple acceptor 
dyes around a central donor QD. Making the assumption that the dyes have a fixed 
average distance from the QD, then Equation 3 can be re-written as the sum of 
multiple non-radiative decay channels, each with the same decay rate [19]: 
E% =	 &'"&'"()*=	

("  !⁄ ,        (6) 
where m is the number of acceptor molecules bound. 
The relationship in Equation 6 is plotted in Figure 6, with the different symbols 
representing acceptors bound at different distances from the donor. By attaching 
multiple acceptors to the donor, EF can be increased dramatically. It should be noted 
that the binding of multiple acceptors provides a means to alleviate the issues of low 
EF at long donor-acceptor distances.  
 
1.2.3.1 Quenching of QD photoluminescence by proximal gold NPs 
The quenching of the QD photoluminescence (PL) in the presence of Au NPs has 
been well-documented, with numerous examples reviewed by Sapsford et al. [4]. 
However, the theoretical basis for the quenching response is still poorly understood 
(in the case of QDs; for dye molecules, a strong predictive model has been described 
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[20]). Pons et al. [21] attempted to determine the nature of the interaction 
experimentally by coupling QDs and Au NPs via a rigid polypeptide linker where the 
separation could be controlled by changing the number of sequence repeats. The 
response was fitted to either a FRET r-6 model, or a nanosurface energy transfer 
(NSET) r-4 model, and it was found that the NSET model explained the data 
qualitatively, but underestimated the effective energy transfer distances. In their 
analysis, Pons et al. suggested that the Au NPs would be able to quench QD PL at 
distances greater than that of FRET acceptors, due to the r-4 dependence of the 
quenching. 
 
1.3 The molecular basis of disease 
One of the most exciting applications of QDs is in biomolecular sensing. In this 
section, the relevance of a number of biomolecular interactions in predicting and 
causing disease is discussed. 
 
1.3.1 Enzyme activity 
Enzymes are proteins whose function is to catalyse biochemical reactions. They 
mediate the signalling processes that control the behaviour of individual cells, and 
hence their activity is critical to the health of an organism. 
Considering those enzymes that mediate post-translational modifications (PTMs) of 
proteins, an enzyme contains: an active site that interacts with the substrate to lower 
the activation energy of a chemical reaction; a substrate binding domain that confers 
specificity by recognising a specific motif on the substrate; and, in many cases, 
structural domains that may also be acted on by other enzymes (see                               
Figure 7 for a structural representation of Gcn5, an enzyme with HAT activity, 
published by Liu et al. [22]). The first type of enzyme-mediated reaction that is of 
interest for this thesis is transferase activity, whereby the active site orients the 
substrate and the enzyme cofactor (e.g. adenosine triphosphate (ATP) or acetyl 
coenzyme A (CoA)) containing a specific functional group, so that the functional 
group can be transferred to the substrate (kinases and acetyltransferases fall into this 
category). The second type of reaction is hydrolysis of the peptide bond between two 




Figure 7. Electrostatic surface representation of Gcn5 HAT. The position of the 
enzyme cofactor within the binding site is shown in yellow, and the conformation of 
the substrate with respect to the protein is shown in green. (Figure from [22]). 
Enzymes can be classified by their substrate and the type of reaction they catalyse, 
and they can also be characterised by their activity i.e. the rate of formation of the 
enzymatic product. The specific activity of an enzyme is defined as the amount of 
product generated per unit time per unit mass of enzyme and is commonly expressed 
in nmol/min/mg enzyme.  
Kinases mediate phosphorylation of their substrates in the presence of the cofactor 
molecule, ATP. Phosphorylation is an important PTM that plays a role in many 
signalling cascades affecting cell growth, the cell cycle, and programmed cell death 
[23]. A number of kinases have been linked to a wide range of cancers, either when 
overexpressed, or when mutated. For example, epidermal growth factor receptor 
(EGFR) is overproduced in two thirds of epithelial cancers, and Ras mutations are 
present in 30% of all cancers [24]. About 20% of all known kinases have oncogenic 
capacity [25].  
Acetyltransferases mediate acetylation of their substrates in the presence of acetyl 
CoA. Histone acetylation has a known role in gene transcription [26] and so has 
become a target of interest for research into cancer progression, with mutations in 
HAT genes linked to colorectal, gastric, pancreatic, and breast cancers [27, 28]. 
Proteases mediate hydrolysis of peptide bonds within their substrates. Proteases have 
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a wide range of functions within the body, including regulation of blood coagulation, 
extracellular matrix (ECM) remodelling, proenzyme activation, and destruction of 
incorrectly folded proteins [29]. As such, aberrant activity of proteases is implicated 
in a number of conditions including HIV/AIDS, cancers, inflammation, and 
cardiovascular complaints [29].  
Kinases, HATs, and proteases are often part of wider signalling cascades, meaning 
that they are important drug targets both individually and in combination. In addition, 
a more accurate diagnosis or prognosis may be obtained by profiling the activities or 
monitoring the levels of multiple enzymes [30]. In biomolecular analysis, highly 
parallel assays are termed ‘multiplex’. The most common are surface-bound DNA 
[31] and protein [32] microarrays, which are used in high-throughput analysis and are 
powerful tools for understanding biomolecular interactions. In the case of NP-based 
assays, detection of two analytes in parallel is sufficient to class an assay as 
‘multiplex’ [33]. 
 
1.3.2 Treatment by administration of small molecules 
One method of treating diseases resulting from the aberrant activity of enzymes is by 
introducing molecules that can modulate the enzyme activity (i.e. inhibitors, or less 
commonly, activators). Kinase inhibition is commonly achieved by administering 
molecules which have a high affinity for the ATP-binding domain of the enzyme. 
Such inhibitors can be highly potent, but often suffer from a lack of specificity. An 
example of one such broad-spectrum inhibitor is staurosporine [34]. Other, more 
specific ATP-competitive inhibitors do exist, but few inhibitors which target the 
protein binding site have been developed [34]. 
In terms of HAT inhibitors, a number of acetyl CoA-competitive molecules have been 
synthesised to inhibit the HATs p300 and p300/CBP-associated factor (PCAF) [35], 
and a broad-spectrum inhibitor, anacardic acid, also exists [36]. In the first case, the 
inhibitor takes the form of a CoA-modified peptide, with the modification appended 
to a lysine residue (since a common HAT PTM is to acetylate lysine residues). In the 
second case, the synthetic molecule possesses significant structural similarity to acetyl 
CoA [37]. Hence, both types of inhibitor are competitive with acetyl CoA binding. 
Proteases do not require a cofactor in order to mediate peptide cleavage, and so 
protease inhibitors must directly target the active site of the enzyme. These inhibitors 
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typically possess structural similarity to the native substrate, whilst also containing a 
motif that interferes with or prevents proteolytic activity. Irreversible inhibitors that 
can chemically alter the active site of the enzyme also exist [29]. 
Design of inhibitor molecules can be guided by structural considerations (aided by 
computer modelling), but for many enzymes (especially those for which structures are 
not known) a more efficient method of inhibitor discovery is HTS. Miniaturisation, 
automation, and small sample volumes are required to assay libraries of 105-107 small 
molecules. In this way, several lead compounds with high potency can be selected for 
further development [38]. Desire for higher fidelity, further miniaturisation, and 
greater automation is currently driving research into novel HTS systems. 
 
1.3.3 Antibodies and specificity 
Antibodies are >150 kDa glycoproteins produced by the immune system that can 
recognise non-native objects that may enter the body. Their structure is illustrated in 
Figure 8 (dimensions are taken from crystallographic studies performed by 
 
Figure 8. Structure of an IgG antibody. Each antibody is composed from two heavy 
chain structures comprising Fc (red) and Fab (orange) domains, linked by a hinge; the 
two heavy chains being connected via dithiol coupling. The light chain domains 
(green) are connected to the heavy chain Fab domains via dithiol coupling. Most of 
the structure is conserved, apart from the two V domains, which bind the analyte and 
confer specificity. (Dimensions marked are in nm, and are taken from [39]). 
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Harris et al. [39] - this paper indicates that the overall antibody can be assumed to 
occupy a maximum volume of ~ 16 nm x 14 nm x 6 nm). 
Antibodies have specificity for specific molecular motifs present on proteins 
(epitopes) that allow them to bind their target (the antigen) with high specificity. 
Antibodies can be raised against a wide range of antigens; their diversity originates 
from the variable regions located at the end of the Fab fragment (VH and VL) [40]. 
The use of antibodies is widespread in all types of immunorecognition assay, mainly 
because it removes the complexity of designing antigen-binding molecules from 
scratch, instead using molecules that nature has evolved over millions of years.  
 
1.4 Assays for determination of enzyme activity 
As discussed in Section 1.3.1, kinases, acetyltransferases, and proteases are 
considered major targets for drug development, with much effort spent on screening 
for inhibitors of these enzymes. In this section, existing state of the art methods for 
evaluation of enzyme activity and inhibitor screening will be discussed. 
 
1.4.1 Kinases 
The major classes of kinase assay have been reviewed by Jia et al. [41] and Olive 
[24]. Some of the most pertinent examples are presented below.  
The ‘gold-standard’ kinase assay is radioisotope labelling [41]. In this type of assay, 
P32-ATP is used as the enzyme cofactor, and hence any phosphorylated substrate will 
also be radioactively labelled. The enzyme substrates are subsequently captured in 
proximity to a scintillant, and the intensity of photons generated indicates the kinase 
activity. This assay is limited by the use of radioactive material and its subsequent 
disposal, as well as the repeated washing steps required to reduce background from 
the free P32-ATP. This limits the assay applicability for HTS applications. 
One of the most widespread biomolecular assays is the enzyme-linked 
immunosorbent assay (ELISA) [42, 43], which has also found application in its 
original [44] and modified [44, 45] versions, for detection of kinase-mediated 
phosphorylation. The concept of the dissociation-enhanced lanthanide fluoro-immuno 
assay (DELFIA®, PerkinElmer, MA, USA) is illustrated in Figure 9, whereby the 




Figure 9. The dissociation-enhanced lanthanide fluoro-immuno assay (DELFIA®, 
PerkinElmer, MA, USA) for detection of kinase-mediated phosphorylation. 
Biotinylated substrate peptides are immobilised on a streptavidin-functionalised 
surface. In the presence of the target kinase and ATP, the peptide is phosphorylated; 
this is recognised by a lanthanide-labelled anti-phospho antibody. Unbound antibody 
is removed by washing. Upon addition of a low-pH enhancer solution, the lanthanide 
is released, resulting in increased fluorescence intensity. 
phospho antibody. Any unbound antibody must be removed at this stage by washing. 
An enhanced signal is subsequently generated by dissociating the lanthanide, resulting 
in increased fluorescence emission. The amount of phosphorylated substrate 
detectable is very low (as little as 0.1 pmole in 200 µL), and hence the assay is 
applicable even for kinases with low specific activity. However, the reproducibility is 
affected by the requirement for thorough removal of unbound antibody. 
The lanthanide chelate excitation (LANCE®, PerkinElmer, MA, USA) assay also uses 
a lanthanide-labelled anti-phospho antibody, but in this case the lanthanide label is 
used as a FRET donor. The use of FRET allows this assay to be homogeneous, with 
the peptides bound on the surface of a fluorescently-labelled bead (again via 
streptavidin (SA)-biotin coupling). Kinase-mediated phosphorylation is recognised 
via antibody binding, which brings the lanthanide donor within the FRET regime. 
Phosphorylation is detected via an increase in acceptor dye emission in a time-
resolved measurement (which allows background fluorescence to decay before signal 
measurement). The sensitivity was found to be similar to that of the DELFIA® assay 
[46]. The lanthanide reagents used in the DELFIA® and LANCE® assays are more 
expensive than standard fluorescent dyes. Nevertheless, the lanthanide-based 
detection assays represent a highly sensitive and powerful means of screening for 
kinase activity.  
Fluorescence polarisation is another technique for monitoring molecular binding 
events. In this format, a small, fluorescently-labelled peptide is used as the enzyme 
substrate; and subsequent phosphorylation is detected via binding of anti-phospho 
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antibodies or NPs displaying trivalent metal ions (immobilized metal-ion affinity 
partitioning, IMAP®, Molecular Devices, CA, USA). The molecular binding event 
slows the rotational motion of the fluorescently-labelled assembly in solution, which 
can be probed using polarised light. The IMAP® assay reagents do not discriminate 
between phosphorylation occurring on different amino acids, which allows a certain 
amount of flexibility in experimental design. However, the metal ions also bind to the 
phosphates contained within ATP, and hence this assay cannot be used in high ATP 
concentrations [47]. A similar principle is used in the IQ assay (Pierce, IL, USA), 
however in this format the trivalent metal ions are coupled to a fluorescence quencher, 
and the measured signal is a decrease in the fluorophore emission. 
A number of systems detecting ATP depletion or adenosine diphosphate (ADP) 
generation have been designed, which make use of the fact that kinase activity not 
only modifies the substrate, but also results in modification of the cofactor. However, 
such assays suffer from lack of specificity, as the conversion of ATP to ADP is 
common to all kinases, and minimisation of the background is difficult, especially in 
complex biological samples [41].  
Finally, a multiplexing format for monitoring phosphorylation of different proteins 
has been developed by Luminex. Polystyrene microspheres loaded with different 
ratios of red/near-IR dyes (each unique ratio identifies a different population of beads) 
are functionalised with antibodies raised against a particular phosphorylated protein. 
Dye-labelled polyclonal secondary antibodies are added to sandwich the analytes of 
interest, and the spectral signatures are read using a microfluidic/laser setup. Non-
specific interactions between antibodies have limited the multiplexing capabilities of 
this assay [24]. 
 
1.4.2 Acetyltransferases 
Since acetyltransferases and kinases belong to the same enzyme class (transferases), 
the mechanism of enzyme modification is fundamentally similar. Hence, the range of 
strategies employed for the detection of acetyltransferases is broadly reflective of 
those discussed above for kinases. A few relevant examples are discussed here. 
In terms of radiometric analysis, the isotope used is reflective of the fact that acetyl 
CoA, not ATP, is the substrate for acetyltransferases. Both H3 and C14 are used to 
label the enzyme cofactor, and in the work of Poveda et al. [48] a limit of detection 
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(LOD) of 1.5 nM p300 HAT was achieved. A time-resolved FRET assay was used to 
monitor acetylation of the protein p53 by p300 HAT, using terbium-labelled anti-
acetyl p53 [49]. The achieved LOD was 0.2 nM p300. It is worth mentioning that the 
antagonistic enzyme family, the deacetylases, are also targets for drug development; 
most of the aforementioned assays can, with minor reagent alteration, be used for 
detection of deacetylase activity [50]. 
 
1.4.3 Proteases 
Proteases are a distinct enzyme family from the kinases and acetyltransferases, in that 
their activity mediates the hydrolysis of specific peptide bonds within protein 
sequences. Since the proteolytic activity causes a physical separation of distinct 
peptide fragments, FRET systems are an attractive means of assaying protease 
activity. In these assays, both termini of a peptide sequence specific to the protease of 
interest are labelled with complementary FRET pair fluorophores. In the literature, 
most examples of FRET pairs that have been used in vivo are recombinantly 
expressed fluorescent proteins [51]. Fluorescence polarisation has also been used to 
detect protease activity; Jolley [52] labelled trypsin substrate peptides with BODIPY 
(red) fluorescent dyes, and monitored the changes in fluorescence polarisation upon 
introduction of the protease, with a detection limit of 10 ng/mL trypsin. 
Mass spectrometry has been used to identify the cleavage fragments of proteases in a 
time-dependent manner [53], however this method requires a significant amount of 
cleavage events before the fragments can be resolved against the substrate. In recent 
years, much interest has focused on NP-based, highly sensitive methods for protease 
detection, some of which are reviewed in Section 1.4.4. 
 
1.4.4 NP-based methods for biomolecular detection 
NPs are emerging as an alternative class of reporter molecule to replace fluorescent 
organic molecules and radioisotope labels in bioassays. NPs possess a number of 
properties that render them ideal biosensing candidates; size- and environment-
dependent optical properties which can be easily distinguished from the background; 
facile bioconjugation chemistries for decorating the NP surface; and high ensemble 
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surface area that boosts the assay sensitivity by binding multiple target ligands. In this 
section, NP-based assays with optical output will be discussed. 
One material that has been commonly used in biosensing assays is Au NPs. The 
preparation of colloidal gold has been known since ancient times [54], but the 
theoretical basis for the characteristic absorbance peak, coherent electron oscillations 
(or surface plasmon resonance, SPR) was first described by Mie in 1908 [55]. The 
Mie theory also predicts a red-shift in the plasmon resonance peak when the inter-
particle separation is decreased to nanometre length scales. Analyte-dependent 
aggregation/dispersion assays that induce shifts in the plasmon peak wavelength have 
been used as the basis for many biomolecular detection systems, some of which are 
outlined below. 
Sandwich-based assays utilising antibody-antigen specificity were described by 
Leuvering in 1980 [56]. Antibodies specific for the target of interest were 
electrostatically bound to the surface of 60 nm Au NPs, and upon the introduction of 
analyte, the solution colour changed from red to blue, indicating immunorecognition- 
induced aggregation of the Au NP assembly. The sensitivity of this method was found 
to be equivalent to that of ELISA, and various optimisations have been reported, 
particularly the method of antibody attachment to improve binding-site exposure [57]. 
A multiplexed assay utilising gold nanorods with separated plasmon peaks has been 
developed by Yu et al. [58]. 
 
Figure 10. Au NP-based protease assay. A - Schematic of the protease-responsive Au 
NP system developed by Laromaine et al. Spheres indicate Au NPs (the resulting 
solution colour is indicated by the shading of the spheres, aggregated solutions appear 
bluer than dispersed solutions.) Aggregation is achieved by self-assembly of Fmoc 
groups on the peptides. Introduction of Thermolysin cleaves the peptides, leaving a 
positively charged fragment, which initiates the dispersion of the NPs. B – spectral 
regions selected to correspond to dispersed (D) and aggregated (A) samples. The ratio 





Figure 11. Schematic of a kinase inhibitor detection assay developed by Wang et al. 
Au NPs are functionalised with Cys-terminated peptides, a proportion of which 
contain an extended kinase substrate sequence. Upon the addition of the kinase and 
biotin-ATP, the substrate is biotinylated. Further addition of avidin-Au NPs causes 
aggregation of the system. Cases 1 and 2 represent absence and presence of the 
inhibitor, respectively. (Figure adapted from [62]). 
Au NP-based sensors have found utility in assays for hydrolases (including proteases 
and endonucleases) because the enzyme activity can disrupt Au NP assemblies, 
resulting in a plasmon peak shift. These assays can exhibit extremely low limits of 
detection, for example, the protease detection assay developed by Laromaine et al. 
[59]. The assay concept is illustrated in Figure 10. Au NPs were decorated with 
peptides susceptible to cleavage by prostate specific antigen (PSA) and terminated 
with a) a cysteine, for attachment to the gold and b) an Fmoc group, for forming self-
assembled NP-NP bridges. In the absence of PSA, the Au NP solution appeared blue, 
and upon the introduction of PSA, turned pink in colour. The absorption spectra were 
monitored to determine the concentration of PSA, and the assay had a LOD of 10 
ag/mL PSA. A similar construction was employed by Song et al. using endonuclease-
specific DNA sequences to probe endonuclease activity and inhibition [60]. In this 
case, it was the hybridisation of single-stranded DNA (ssDNA) that stabilised the Au 
NP assemblies. 
Activity-dependent assays for kinase detection by Au NPs require a mechanism for 
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kinase-mediated NP aggregation. Three examples are: substrate peptide-decorated Au 
NPs and anti-phosphotyrosine antibody-labelled Au NPs which aggregate due to 
kinase-mediated phosphorylation [61]; biotinylated ATP, substrate peptide-decorated 
Au NPs and avidin-labelled Au NPs which aggregate due to the kinase activity 
appending a biotin to the peptide and subsequent biotin-avidin coupling [62] (see  
Figure 11); and negatively-charged Au NPs aggregated by cationic substrate peptides 
– phosphorylation renders the peptides anionic, provoking Au NP dispersion [63]. 
Au NP-based sensing strategies have been incredibly successful in vitro, however the 
absorbance-based measurement can be susceptible to background noise from 
biological components. In addition, it can be difficult to control the size of NP 
assemblies, meaning that there is an inherent inhomogeneity present in such systems. 
The prevalence of Au NP-based biosensing strategies inspired the design of 
alternative NP-based assays, using different classes of material exploiting optical 
properties such as fluorescence, and not requiring the formation of NP assemblies. 
 
1.4.4.1 QDs in biosensing 
QDs possess size-dependent fluorescent emission, and bioassay design utilising QDs 
relies on the modulation of the emission spectrum via a number of different 
mechanisms. The state of the art in QD-based biosensing has been reviewed by 
Freeman et al. [64] and Algar et al. [65].  
One of the uses of QDs is to replace traditional fluorophores in ELISA-type assays. 
Kerman et al. [66] used a sandwich assay to detect PSA, making use of biotinylated 
secondary antibodies and SA-labelled QDs. The LOD was found to be 0.25 ng/mL 
PSA, which represents a 100-fold higher sensitivity than the alternative assay utilising 
fluorescein isothiocyanate (FITC). One of the commonly-stated advantages of QDs is 
that multiple emission wavelengths can be excited simultaneously, allowing for 
multiplexed detection. In a demonstration of this concept, Goldman et al. [67] carried 
out a sandwich assay for four different analytes using four different colours of QDs. 
Here, the reporter antibodies were immobilised onto the QDs using a protocol 
developed by the same group [68]. Another property of QDs is that the emission can 
be altered in response to phenomena occurring on the nanoscale, close to the surface 
of the NP. QD-based assays have been demonstrated in a multitude of formats, 




Figure 12. Schematic of maltose sensor developed by Medintz et al. 1) The QD 
surface is decorated (via His tag-metal coordination) with multiple copies of the 
biological substrate (2), maltose binding protein. The QD emission is quenched by the 
binding of β-cyclodextrin-QSY (QSY being a molecular quencher), which is 
displaced (3) in the presence of maltose. 4) Presence of the target, maltose, effects a 
spectral change in the QD emission. (Adapted from [15]).  
energy transfer (BRET) [33], chemiluminescence resonance energy transfer (CRET) 
[75], fluorescence quenching by organic quenchers [15] or proximal Au NPs [76], and 
charge transfer [77, 78]. 
The targets of these QD-based sensors are equally diverse, but a good introduction to 
many of the common concepts is provided by the maltose sensor developed by 
Medintz et al. [15], which is illustrated in  Figure 12. Typically, signal enhancement 
is achieved by decorating the QDs with multiple biomolecules, which serve as a 
substrate or binder of the target analyte. Upon introduction of the analyte, a 
modification in the substrate/binding molecule results in alteration of the emission 
spectrum of the QDs which allows the analyte to be detected. In the case of the 
maltose sensor, QDs were decorated with His-tagged maltose binding protein (MBP) 
which was blocked with QSY-labelled β-cyclodextrin. QSY is a molecular quencher 
with a strong overlap with the QD emission, and induces a drop in the QD PL. Upon 
introduction of maltose, the weakly-bound β-cyclodextrin-QSY is displaced, 
destroying the quenching interaction and causing recovery of the PL. 
QDs have been used in assays for determination of the enzymatic activity of kinases 
[72, 73], HATs [74], proteases [33, 70, 71, 76-78], and multiplex combinations 




Figure 13. QD-FRET assay for tyrosine kinases. His-tagged kinase substrate peptides 
are used to functionalise the QD surface via self-assembly (multiple copies of the 
peptide are present on the QD surface, only one peptide shown for clarity). Upon the 
introduction of the target kinase and ATP, the substrate peptide is specifically 
phosphorylated. The modification is detected via immunorecognition with acceptor 
dye-labelled anti-phosphotyrosine antibodies, resulting in FRET between the QDs and 
the proximal dyes. (Adapted from [72]). 
 
Figure 14. QD fluorescence quenching/recovery assay for proteases. Au NP labelled, 
biotinylated substrate peptides are used to functionalise the streptavidin-labelled QD 
surface via self-assembly (multiple copies of the peptide are present on the QD 
surface, only one peptide shown for clarity). The proximal binding of Au NPs 
quenches the emission of the QDs. Upon the introduction of the target protease, the 
substrate peptide is specifically cleaved. The modification is detected via an increase 
in the QD emission. (Adapted from [76]). 
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enzyme is active; the assay would be able to distinguish between latent and active 
forms of the enzyme. 
Ghadiali et al. [72] used CdSe/ZnS core-shell QDs with an emission maximum of 605 
nm (QD605s) in their assays for the tyrosine kinases Src and Abl. The assay concept 
is illustrated in Figure 13. The QDs were decorated with multiple copies of His-
tagged substrate peptides which were designed to be specifically recognised by either 
Src or Abl kinase. Upon the introduction of kinase and ATP, the surface-bound 
peptides were specifically phosphorylated at the tyrosine residues.  Monoclonal anti-
phosphotyrosine antibodies were labelled with AF dyes with an absorption maximum 
of 647 nm (AF647); there is a significant spectral overlap between the QD605 
emission and the AF647 absorption. In order to develop the kinase-dependent signal, 
the AF647-labelled antibodies were added, and the subsequent immunorecognition 
brought the dyes within the distance regime for FRET. The spectral response was a 
decrease in the QD emission, accompanied with the onset of dye emission at 670 nm. 
The fluorescence lifetime of the QDs was monitored in the presence and absence of 
ATP, confirming that the decrease in fluorescence lifetime (due to FRET) only 
occurred in the presence of ATP. This indicated that the assay was activity dependent. 
The FRET response in the presence of kinase inhibitor staurosporine was reported by 
calculating the ratio between the emissions at 670 nm and 605 nm, showing a typical 
dose-response curve and allowing for calculation of the IC50 (inhibitor potency). 
Finally, the LOD was reported, given as an enzyme activity of low fmol/min/µL 
enzyme reaction.    
Kim et al. [76] developed a QD-based protease detection system using CdSe/ZnS 
core-shell QDs with varying emission wavelengths, and 1.4 nm Au NPs as quenchers 
of the QD emission. The assay is illustrated schematically in Figure 14. The proteases 
investigated were matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-7 
(MMP-7), caspase-3, and thrombin. Peptides with the general structure (biotin)-
(protease cleavable sequence)-(cysteine) were synthesised and labelled with 1.4 nm 
Au NPs via the thiol present in the cysteine. The QDs were subsequently decorated 
with the peptides, resulting in quenching of the QD emission due to proximal binding 
of the Au NPs. Upon the introduction of protease, specific cleavage of the peptides 
occurred, releasing the Au NPs and resulting in recovery of the QD emission. Finally, 
the assay was demonstrated in a multiplexed format by immobilising QDs with 
different emission maxima on a surface and functionalising each with a substrate 
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peptide recognised by a specific protease. Incubation with each protease in turn 
resulted in specific recovery of QD emission from just one type of QD, revealing the 
identity of the protease. Protease multiplexing using QD-BRET [33] and QD charge 
transfer [78] has also been demonstrated. Such multiplexed assays could be used to 
characterise mixtures of enzymes and determine biomarker profiles in clinical 
samples. 
 
1.4.4.2 NPs in biomarker multiplexing 
In addition to the examples mentioned above, NPs have been used to perform 
multiplexing of biomolecules. There are various methods used to achieve specific 
recognition and avoid signal cross-talk, and a number of pertinent examples are 
discussed here. 
Kim et al. [80] developed an aptamer-based detection system for mercury ions, 
potassium ions, and adenosine molecules. The assay is illustrated in Figure 15. The 
aptamers were ssDNAs with high specificity for the target of interest, which were 
covalently conjugated to the surface coating of QDs.  Differentially-emitting QDs 
were decorated with an aptamer specific to a unique target. The QD-ssDNA 
conjugates were incubated with 100 nm-diameter Au NPs, and the ssDNA adsorbed 
electrostatically to the Au NP surface. Proximal binding of the QDs and Au NP 
quenched the QD emission. Upon the introduction of the specific analyte, a  
 
Figure 15. Aptamer-based multiplexing assay for biomolecular targets. QDs labelled 
with DNA aptamers are mixed with unmodified Au NPs to form an Au NP-DNA-QD 
complex stabilised via electrostatic interactions, with low QD emission. Upon 
introduction of the biomolecular targets, conformational change of the aptamers 
displaces the QDs from the Au NP, and QD emission is recovered. Multiplexed 
detection is achieved by decorating QDs with distinct emission spectra with analytes 




Figure 16. Schematic illustration of multiplexed DNA hybridization assays using QD-
tagged beads. Streptavidin-coated 1.2 µm polymer beads are loaded with differing 
ratios of CdSe/ZnS core/shell QDs. Biotinylated probe oligonucleotides are 
conjugated to the beads by covalent linkage, while target oligonucleotides are non-
specifically labelled with a blue fluorescent dye. Target binding is detected by 
observing the dye peak alongside the bead spectrum, which identified the target 
sequence (graphs to the right). The use of 10 intensity levels and 6 colours could 
theoretically code one million nucleic acid or protein sequences. (Figure reproduced 
from [81]). 
conformational change in the ssDNA allowed the binding of the analyte and also 
displaced the QD from the Au NP. Hence, the binding of the analyte resulted in a 
recovery of QD emission at a wavelength specific to the analyte of interest. No off -
target interactions were observed when multiple QD-ssDNAs were incubated with a 
single analyte, or multiple analytes. 
Han et al. [81] developed a multiplexed probe for DNA sequences, using polymer 
beads loaded with 3 differentially-emitting QDs, at varying emission intensity ratios, 
as shown in Figure 16. The emission intensity profile of each bead represented an 
optical code for bead identification. Each code corresponded to the specific probe 




Figure 17. Example of multiplexed and amplified detection, where DNA-
functionalised magnetic and gold particles are used to sandwich multiple target DNA 
sequences in solution. 30 nm Au NPs are loaded with ssDNA sequences comprising 
universal and specific (barcode) portions. The “barcodes” are used to uniquely 
identify each target. Magnetic microparticles (MPs) are each functionalized with a 
separate ssDNA sequence which binds a different portion of the same targets as the 
Au NP probes. In the first step, the magnetic MPs are incubated with a number of 
different DNA targets. Upon Au NP probe addition, magnetic MP-analyte-Au NP 
sandwiches form. A magnetic field is then used to separate bound Au NPs from the 
unbound, subsequently the barcode DNA is released from the bound Au NPs and 
transferred to a complementary DNA array for detection. Notably, for each bound 
analyte multiple barcodes are released (signal amplification). (Figure adapted from 
[86]). 
sequences were non-specifically labelled with a fluorescent dye (‘analyte’ label), 
before the optically coded beads were introduced. After incubation, the beads were 
probed individually via single-particle spectroscopy. Probe-target hybridisation was 
detected via the presence of the ‘analyte’ peak, and the identity of the sequence was 
revealed by deciphering the optical code. Similar assays have been demonstrated by 
Xu et al. [82] and Niu et al. [83].  
One of the most sensitive multiplexed detection systems demonstrated to date is the 
‘bio-barcode’ assay developed by the Mirkin group [84-86]. This assay is illustrated 
in Figure 17, and makes use of Au NPs loaded with multiple ssDNA sequences 
(barcodes) binding complementarily to a portion of the DNA target of interest. Upon 
hybridisation with magnetic microparticle probes, the bound complexes can be 
separated via a magnetic field, and the barcode DNA released, amplifying the signal. 
In another iteration of the assay, the Au NPs are co-loaded with analyte-specific 
antibodies and ssDNA sequences specifically identifying the target of interest (the 
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‘barcode’). The multiplexed assay was demonstrated for the simultaneous detection of 
PSA, human chorionic gonadotropin, and α-fetoprotein. The individual assay for PSA 
has a detection limit of 330 fg/mL.  
1.4.5 Summary 
In this section, biomolecular assays have been considered in terms of their design 
sensitivity, ease of use, and general applicability. There are well-established assays 
for kinases, acetyltransferases, and proteases, some with sub-nM limits of detection, 
allowing them to potentially be used in clinical diagnostic applications. However, the 
assays often suffer from complicated sample preparation, cumbersome washing steps, 
high cost, and lack of automation (a skilled operator is required for many of the 
assays). Several NP-based assays have emerged in response to these drawbacks, 
which have demonstrated high sensitivity (some with limits of detection 
corresponding to just a few tens of molecules per sample) with relatively simple 
sample preparation. In addition, the use of NP physical properties affords the 



















2 Activity-dependent assay for p300 HAT 
2.1 Introduction 
In this chapter, a QD-based system for the detection of p300 HAT is described. One 
of the motivations behind developing a QD-based assay for HATs was to demonstrate 
the generic nature of the kinase-actuated FRET sensor published by Ghadiali et al. 
[72] and described in Section 1.4.4.1. By modifying the assay components, the 
intention was to re-engineer the sensor for the detection of diverse enzyme families. 
Acetyltransferases, like kinases, catalyse the transfer of chemical groups from enzyme 
cofactors to target amino acids within proteins. An important subset of 
acetyltransferases is the HATs, which facilitate the covalent attachment of an acetyl 
group to the ε-amine of lysine residues in histone tail sequences (see Figure 18 and 
Figure 19).  
HATs have significance with respect to health due to their effect on regulation of 
DNA transcription. Figure 19 shows the basic structural unit of DNA compaction in 
the eukaryotic cell, the nucleosome [87]. Short sequences of bases are wrapped 
 
Figure 18. Acetyltransferase reaction scheme. Lysines within the enzyme recognition 
sequence are acetylated in the presence of acetyltransferases and acetyl CoA. Inset - 




Figure 19. Structure of the nucleosome. Histones are a fundamental component in the 
compaction of DNA in the nucleus. They serve as a scaffold for DNA binding, and 
their affinity can be modulated as a result of enzymatic activity on the histone tail 
peptides protruding from the protein core. (Figure adapted from [87]). 
around protein complexes called histones. Extending from the histone core are short 
peptide sequences (histone tails) susceptible to PTMs, which influence the 
interactions of nucleosomes in the packaging of DNA and hence the accessibility of 
genes for transcription [88]. Relevant PTMs include phosphorylation, acetylation, 
methylation and ubiquitination, which make up a supra-genomic pattern, dubbed the 
‘histone code’ within the field of epigenetics [89]. Acetylation is of interest for a 
number of reasons. Firstly, and most pragmatically, acetylation is a fundamentally 
similar process to phosphorylation and represents a sensible analogue for testing the 
transferability of the assay concept. By contrast, methylation of histone tail residues 
can be di- or trivalent, adding a layer of complexity which would be inappropriate for 
a proof-of-concept [90]. Additionally, ubiquitination is a multi-stage modification 
which might prove time-consuming to optimise for a NP-based assay. Focusing on 
health implications, HATs have been implicated in diseases such as cancer, 
neurological disorders, chronic inflammation, and HIV/AIDS and hence present an 
attractive drug target [91-94]. p300 is a HAT that is known to acetylate the tails of all 
four histone subunits [95]. A link between p300 HAT and the progression of prostate 
cancer has been suggested [96]. In this study, the histone-H4 tail was selected as the 
p300 HAT substrate. 
In order to detect p300 HAT, a QD-based approach was used (the experimental 
procedure is set out in Figure 20). As discussed in Section 1.2.2.2, QD optical 
properties are superior to that of traditional organic dyes, with strong resistance to 
photobleaching and a wide excitation spectrum in the UV range (which makes them 
ideal FRET donors, as indirect excitation of the acceptor can be eliminated 




Figure 20. QD FRET-based detection of p300 HAT activity. Lysine-containing 
histone tail substrate peptide was incubated with a) p300 HAT and acetyl CoA at 30° 
C and b) CdSe/ZnS core/shell quantum dots and dye-labelled anti-acetyllysine. 
Bioconjugates formed by His tag-metal affinity coordination (multiple peptides per 
QD; one peptide shown for clarity), and antibody-antigen biorecognition allowing for 
dye-QD FRET. 
for synthetic p300 substrate peptides; the nanoscale dimensions of the QDs increase 
the ensemble surface area available for sensing. The p300 substrate peptides possess 
dual functionality, with enzyme specificity imparted via a recognition sequence, and 
attachment to QDs mediated via a His tag. Activity of p300 HAT is detected via 
immunological recognition of acetylation on the peptide, using acceptor dye-labelled 
anti-acetyllysine antibodies to develop a FRET signal. The assay is activity dependent 
because the antibody only recognises acetylated peptides. Peptides can be 
immobilised on the QD before or after treatment with p300 HAT, and both formats 
were tested. 
 
2.1.1 Scope of Chapter 
This chapter deals with the major concepts, materials and methods used to develop an 
assay for p300 HAT, which in turn form the foundation for the assays developed in 
Chapters 3 and 4. 
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Described herein are the steps taken to convert an existing platform for kinase 
detection into an assay for p300 HAT. The objective of the study was to assess the 
effect of changing key parameters such as peptide-QD ratio, antibody-QD ratio, 
temporal sequence of reagent addition, and enzyme incubation time on the stability of 
the QD assemblies and the sensitivity of the assay. The assay was also tested in a 
drug-screening format using a small molecule inhibitor of p300 HAT activity. 
 
2.2 Materials + Methods 
2.2.1 Materials 
CdSe/ZnS core-shell QDs (1 µM in decane) with a nominal emission wavelength of 
605 nm (QD605) and amine-reactive fluorescent dye, AlexaFluor 647 carboxylic acid, 
succinimidyl ester, (AF647-NHS) were purchased from Life Technologies (Paisley, 
UK). p300, HAT domain was purchased from Millipore (Watford, UK). It was 
aliquoted and stored at -20 ºC before use. Anacardic acid was purchased from Enzo 
Life Sciences (Exeter, UK) and was resuspended in anhydrous dimethyl sulphoxide 
(DMSO) before storage at -20 °C. Mouse monoclonal anti-acetyllysine IgG antibody 
(1 mg/mL in 0.1% w/v Sodium azide/PBS solution) was purchased from Abcam 
(Cambridge, UK). DMSO (99.9%), tetramethylammonium hydroxide pentahydrate, 
TMA (97%), 3-mercaptopropionic acid, MPA (99%), methanol (99.8%), isopropanol 
(99.8%), boric acid, ethylenediaminetetraacetic acid, EDTA, lyophilised bovine 
serum albumin, BSA (96%), and acetyl CoA (trilithium salt) were purchased from 
Sigma-Aldrich (Gillingham, UK). Chloroform (99%), Tris buffer and glycerol were 
purchased from VWR (Poole, UK). Agarose was purchased from Helena Biosciences 
(Gateshead, UK). Borate buffer tablets were purchased from Fisher Scientific 
(Loughborough, UK) and 50 mM borate buffer was prepared by dissolving one tablet 
per 100 mL deionised water (Purite), then adjusting the pH to 9.6. 
 
2.2.2 QD capping layer exchange 
The QD605s are supplied in decane with a TOP/TOPO capping layer. In order to 
render the QDs soluble in aqueous buffers, the hydrophilic ligand MPA is exchanged 
onto the QD surface by the protocol of Pong et al. [14], with minor modifications. 
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The QDs were precipitated and resuspended in chloroform as follows: QDs (100 µL, 
1 µM) were added to a mixture of methanol and isopropanol (900 µL, 3:1 ratio by 
volume) and mixed well before centrifugation at 10,000g for 2 mins (Eppendorf 
5804R). The supernatant was removed and chloroform (1.0 mL) was added to 
resuspend the QDs. Separately, TMA (1.0 g) was weighed into a 50 mL 
polypropylene falcon tube. MPA (500 µL) and chloroform (9.0 mL) were then added 
and the mixture was shaken gently to dissolve the TMA. After the mixture had been 
left to stand at RT for 1 hour, the mixture was centrifuged at 3,000g for 5 mins, 
causing the mixture to separate into two well-defined phases. The organic phase (10 
mL) was transferred to a new 50 mL falcon tube using a 230 mm glass Pasteur pipette 
(Fisherbrand, Loughborough, UK). The chloroform-suspended QDs were added and 
the mixture was left at RT for 40 h. Borate buffer (10 mM, pH 9.6, 10 mL) was added 
to this mixture and the two phases were separated by centrifugation at 3,000g for 5 
mins. The organic phase was removed using a glass Pasteur pipette. Chloroform (10 
mL) was added and the mixture was again centrifuged at 3,000g for 5 mins. Organic 
phase removal, chloroform addition and centrifugation were repeated a second time to 
ensure the removal of organics from the aqueous phase. The remaining organic phase 
was removed a final time, and the aqueous dispersion of QDs was transferred to a 10 
mL, 10 kDa MWCO centrifugal filtration tube (Millipore, Massachusetts, USA) in 
order to remove excess MPA. The dispersion was centrifuged at 5,000g for 12 mins to 
leave 1 mL of retentate. Borate buffer (9.0 mL) was added and the dispersion was 
filtered and resuspended again before a final filtration. The centrifugal filtration steps 
can be repeated to exchange the QDs into a buffer of choice. For long-term storage, 
the resulting retentate was collected and kept at 4 °C. Concentration determination 
was carried out using UV/Visible spectroscopy (see Section 2.2.6.1). 
 
2.2.3 Peptides 
2.2.3.1 Peptide design 
The p300 substrate peptide has the following sequence: 
RGKGGKGLGKGGAKAHHHHHH-NH2 (C-terminal amidation), with a predicted 
molecular weight of 2163.4 Da, and a charge at pH 8.0 of +6e [97]. 
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The peptide architecture consists of two functionalities – an enzyme recognition 
sequence, and a self-assembly motif. As detailed in Section 2.1, p300 HAT is 
responsible for the acetylation of histone tail sequences in chromatin. For the purposes 
of this assay, a sequence from the tail of the histone H4 subunit, based on the study of 
Thompson et al. [98] was selected. The effect of p300 HAT is to facilitate the transfer 
of acetyl groups to the ε-amine of lysines. Thompson et al. observed that the preferred 
acetylation site for this sequence was K6, but acetylation of other lysines was also 
detected. In terms of the molecular properties of the peptide, the effect of lysine 
acetylation is to increase the molecular weight by +42 Da and decrease the total 
charge by -1e per acetyl group.  
The C-terminal portion of the peptide is composed of a His tag, known to interact 
strongly with the ZnS surface of QDs via metal-affinity coordination [15]. With 
respect to the sequence derived from the study of Thompson et al., described above, a 
hydrophobic alanine spacer is included after the His tag, to avoid any deleterious 
effects of the positively charged lysine residue and to promote binding of the His tag 
to the QD surface. 
 
2.2.3.2 Peptide synthesis 
p300 substrate peptide was synthesised by Solid-Phase Peptide Synthesis (SPPS) [99], 
using Fmoc-protected amino acid monomers and HOBt/HBTU activation on a peptide 
synthesiser 433A (Applied Biosystems, California, USA).  In each coupling step, a 
10-fold excess of amino acids was used. Cleavage from the resin and side-group 
deprotection was performed using trifluoroacetic acid and triisopropylsilane. The 
peptide was purified using a high performance liquid chromatography (HPLC) system 
model GX-271 (Gilson, Sollentuna, Sweden). A c18 reverse-phase HPLC column was 
used with a gradient of acetonitrile and water. A flow rate of 9.98 ml/min was used 
and fractions were collected in eppendorf tubes. The peptide samples were lyophilised 
and analysed via matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry courtesy of the Chemistry Department, Imperial College London, using 
a MALDI micro MX (Micromass, Manchester, UK). The lyophilised peptides were 
reconstituted in ultrapure deionised water (Purite) to a concentration of 1 mM, 




2.2.3.3 MALDI Mass Spectrometry 
MALDI is a mass spectrometry technique well-suited to the analysis of biological 
molecules [100]. Typically, an acidic matrix acts as a proton donor to the molecule of 
interest, while absorbing much of the incident laser energy. The intact, ionised peptide 
is vaporised along with the volatile matrix, and can be subsequently detected using 
time-of-flight mass spectrometry. Mass peaks are observed at m/z of (P+n)/n, where n 
is an integer corresponding to number of protons added, and P is the peptide 
molecular weight. Peaks are often observed at m/z = P+23, due to the incorporation of 
sodium ions present in some samples.  
 
2.2.3.4 Chemical acetylation of peptide 
For the purpose of optimising the assay conditions, a positive control peptide was 
prepared by chemical acetylation of the p300 substrate peptide (referred to in the 
remainder of this chapter as Ac-p300 peptide), based on the protocol of Hermanson 
[101]. A 2 mg/mL solution of p300 substrate in 0.1 M sodium phosphate, pH 7.5, was 
prepared. While mixing the solution via magnetic stirring, aliquots of acetic anhydride 
up to a molar excess of 10:1 were added. The solution was left to react on ice for 2 h, 
and was subsequently stored at 4°C. The extent of acetylation was determined via 
MALDI mass spectrometry.  
 
2.2.4 Preparation of bioconjugates 
2.2.4.1 Dye-Antibody conjugation 
The AF647-NHS dye was conjugated to the anti-acetyllysine antibody as per the 
manufacturer’s instructions. The dye molecules are expected to attach covalently and 
in a stochastic manner to any free amines present in the antibody. The dye-
functionalised antibodies were purified by using a Zeba Spin desalting column with a 
40 kDa MWCO (Thermo Fisher, IL, USA) to remove unreacted dye. The coupling 
efficiency was determined by performing absorbance spectroscopy on the remaining 
dye-labelled antibody filtrate. It was assumed that the filtration process removed any 
unreacted dye. The dye concentration was determined using the peak extinction 
coefficient provided by the manufacturer (see Sections 2.2.6.1 and 4.2.4). The 
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antibody concentration was determined by recording the absorbance at 280 nm and 
subtracting contribution from the dye absorbance (correction factor provided by the 
manufacturer). The antibody extinction coefficient used was 203,000 M-1cm-1. 
 
2.2.4.2 Conjugation of peptides to QDs 
QDs and peptides were conjugated in 50 mM Tris-HCl buffer (pH 8.0), 0.1% w/v 
BSA, at RT. Buffer exchange from borate to Tris-HCl buffer was carried out via 
centrifugal filtration, as described in Section 2.2.2. In order to conjugate peptides onto 
QDs, solutions were mixed in the desired molar ratio and incubated at RT for 60 mins. 
The bioconjugates were probed using gel electrophoresis (Section 2.2.5). Conjugate 
stability was investigated by subjecting the conjugates to centrifugation at 16,000g for 
1 minute. Pelleting and precipitation of QDs was taken to be an indication that the 
bound ligand had a detrimental effect on the colloidal stability.   
 
2.2.5 Gel electrophoresis 
Electrophoretic techniques are used to separate charged molecules in solution by 
virtue of differing molecular mobilities under the application of an electric field. Gel 
electrophoresis is performed in a porous gel matrix which enhances the separation 
effect and biases the mobility in terms of molecular size. Larger molecules with more 
extended conformations must take a more tortuous path through the gel, lengthening 
their migration time. At a fixed time point, determined by the operator, the electric 
field is removed, and the position of the molecules within the gel can be elucidated by 
dye staining, or in the case of fluorescent molecules, by illumination with UV 
radiation. One of the more common gel matrix materials is agarose, which is 
polymeric and can form networks of pores with different sizes dependent on w/v 
percentage of agarose used. The running buffer affects the resolution of separation in 
the gel. In this work, a common running buffer (Tris/borate/EDTA, TBE), used for 
separating DNA samples in gels, is employed. 
10x TBE – 106 g Tris, 55 g boric acid, 40 mL EDTA (0.5 M), pH 8.0 was prepared 
and made up to 1 L with deionised water. 100 mL of 10x TBE was diluted to 1L for a 
1x TBE solution. For a 2% w/v agarose solution, 2 g agarose was added to 100 mL of 
1x TBE. The solution was stirred well then heated in a microwave on high power for 
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2 mins. The solution was poured into a gel cast and a comb was added to form the 
sample wells. After 30 mins, the solid gel was transferred to a gel box (Bio-Rad, CA, 
USA) and covered with 1x TBE buffer. The sample was mixed with glycerol to a final 
concentration of 25% v/v to prevent diffusion out of the wells, and the electric 
potential was set to 150 V for 30 mins.  The gels were exposed to UV 
transillumination and imaged using a on a BioSpectrum 500 fluorescence reader from 
UVP (CA, USA). 
 
2.2.6 Spectroscopic methods for materials characterisation 
Concentrations of NPs and biomolecules can be assessed using spectroscopic 
methods, as many molecules have quantifiable optical absorbance peaks, and some 
have fluorescent activity. For most QD-based biomarker assays, changes in the 
fluorescence spectra are used as the basis for analyte detection; this technique is also 
used in the experiments described herein. See Section 1.2 for a description of 
fluorescence and fluorescence spectroscopy. 
 
2.2.6.1  UV/Visible absorbance spectroscopy and fluorimetry 
UV/Visible absorbance spectroscopy was carried out using a NanoDrop 2000c with 
cuvette capability (Thermo Scientific, DE, USA) and quartz cuvettes (Hellma 
Analytics, Germany). 
Absorbance spectroscopy makes use of the fact that molecules absorb energy from 
incident photons, with a characteristic pattern dependent on the molecule. In an 
optical medium, this leads to a decrease in the transmitted intensity as light of a 
particular wavelength propagates. 
 
Molecule ε(280 nm) / M-1cm-1 ε(650 nm) / M-1cm-1 ε(600 nm) / M-1cm-1 
AF647 dye     7,170 239,000 n. a. 
IgG antibody 203,000 negligible n. a. 
QD605 n. a. n. a. 650,000 
Table 2: Molar extinction coefficients for molecular species used in this chapter. 




The absorbance, A, is related to the physical properties of the medium by the Beer-
Lambert law (Equation 7):  
G = − log3L L3⁄  = MNO        (7) 
where   
I = transmitted intensity at wavelength λ 
I0 = incident intensity at wavelength λ 
ε = molar extinction coefficient 
c = molar concentration of solution 
L = path length through the optical medium. 
The path length of the cuvettes used in the spectrometer is 10 mm. Using published 
extinction coefficients, UV/Visible spectroscopy is used to determine the 
concentration of prepared solutions. The relevant values for this study are listed in 
Table 2.    
Fluorescence spectra were recorded in the spectrophotometer mode using a 
SpectraMax M5 microplate reader with an excitation wavelength 405 nm and cutoff 
filter at 435 nm. 
 
2.2.7 Protocol for p300 HAT activity assay 
The p300 peptide substrate was incubated with p300 HAT and acetyl CoA with 20 
µM peptide and 200 µM acetyl CoA at 30 °C. The p300 HAT supplier recommended 
a reaction buffer of 50 mM Tris-HCl at pH 8.0. 0.1% w/v BSA was added to aid 
stability of the QDs in subsequent steps. Peptides were incubated with p300 HAT 
either: a) free in solution (off-dot) or b) pre-conjugated to QD605 (on-dot). In case a), 
QD605 conjugation followed immediately after the enzyme reaction. QD-peptide 
conjugates were treated with dye-labelled antibody at specific antibody-QD ratios for 
the development of FRET signal. 10 µL aliquots of the QD-peptide mixture were 
loaded on a black 384-well plate (Corning, MA, USA). Fluorescence spectra in the 
region 570 nm – 700 nm were recorded as described in Section 1.2.1.1. 
 
2.3 Results 
In this section, system characterisation, signal optimisation, and demonstration of the 
assay are reported. The dynamic range of the assay and LOD were determined, and 
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the assay was used to determine p300 specific activity and potency of the p300 
inhibitor, anacardic acid. These results are discussed in the context of existing 
methods for the detection of p300 HAT. 
 
2.3.1 Peptide synthesis 
 
Figure 21. MALDI mass spectral analysis of synthetic peptides. A. Chemical structure 
of p300 substrate peptide. B. MALDI mass spectrum for p300 substrate peptide, with 
the labelled ionisation peaks (P+H+/Na+) indicating a peptide molecular weight of 
2163 Da. C. MALDI mass spectrum for p300 substrate peptide treated with acetic 
anhydride; the labelled peak (P+5Ac+H+) has shifted by 210 Da, corresponding to 





p300 substrate peptide (Figure 21A) and Ac-p300 peptide were analysed by MALDI 
mass spectrometry. Figure 21B indicates the mass spectrum for p300 substrate 
peptide, with a peak at the expected MW of 2163 Da. The results of treatment with 
acetic anhydride are shown in Figure 21C – a peak at 2373 Da indicates that all 5 free 
amines in the peptide (4 lysine residues and the N-terminal amine) were acetylated 
with a yield of close to 100%, as there is no peak apparent at 2163 Da. 
 
2.3.2 MALDI mass spectrometry to validate p300 activity 
The activity of p300 HAT was probed by MALDI analysis of the enzymatic products, 
after incubation of p300 substrate peptide with 640 nM p300 HAT and acetyl coA for 
6 h, as described in Section 2.2.7. The MALDI trace is shown in Figure 22. By 
comparison with the MW of free p300 substrate peptide, there are peaks at mass shifts 
of +42 Da and +84 Da, corresponding to transfer of one or two acetyl groups, 
respectively. The MALDI data indicate that p300 HAT is able to acetylate the 
synthetic p300 substrate peptide in solution and that the peptide can be acetylated at 
multiple sites. This fits with the trend observed by Thompson et al. [98]. 
 
Figure 22. MALDI mass spectrum of p300 substrate peptide after incubation with 
p300 HAT and acetyl CoA. a and b - peaks corresponding to mass shift of +42 Da (1 
acetyl group) and +84 Da (2 acetyl groups) respectively with respect to initial 
molecular weight of p300 substrate peptide (peaks at +22 m/z with respect to a and b 
are sodium adducts). The matrix used was alpha-cyano 4-hydroxy cinnamic acid.  
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280 0.578 0.517 2.5 
AF647 dye 650  2.02 2.02 8.5 
Table 3: Absorbance of dye-antibody conjugates, measured by UV/Visible 
spectrometry. The concentrations were determined using the molar extinction 
coefficients listed in Table 2. *The corrected absorbance was calculated as detailed in 
Section 2.2.4.1. 
 
The yield of the dye-antibody coupling reaction was quantified via absorbance 
spectroscopy. After purification of the dye-labelled antibody, the respective 
concentrations of AF647 and anti-acetyllysine IgG were determined. It was assumed 
that all unreacted dye had been removed due to the purification process. Molar 
extinction coefficients at relevant wavelengths are given in Table 2.  
Representative data for a single labelling is shown in Table 3. Note that the peak 
signal at 280 nm (IgG absorbance) must be corrected for off-peak dye absorbance. 
From this data, the dye-antibody ratio was calculated as 3.4, which represents a yield 
of 34 % (considering an initial molar ratio of 10:1).  
 
2.3.4 Peptide-QD conjugation 
Non-covalent self-assembly was used to prepare QD-peptide conjugates. The 
interaction of QD605s with the p300 substrate peptide was investigated using agarose 
gel electrophoresis, as described in Section 2.2.5. Under fluorescent illumination, the 
progress through the gel of QD605s conjugated with varying molar ratios of p300 
substrate peptides was observed (shown in Figure 23). QD605s capped with MPA 
alone (left lane labelled ‘0’ in the fluorescence image) are negatively charged and run 
towards the anode. As the ratio of peptide to QD is increased, the progress of the 
QD605s through the gel is hindered. This can be attributed to charge and size effects. 
At pH 8.0, each p300 substrate peptide contains a charge of +6e and hence self-
assembly of peptides on the QD surface reduces the net charge. In addition, the 
introduction of large numbers of peptides considerably increases the conjugate size, 
further affecting the mobility. The combination of these effects gives a qualitative 





Figure 23. Fluorescence table image of 1% agarose gel containing QD605-p300 
substrate peptide conjugates in 50 mM Tris-HCl pH 8.0. Numbers indicate peptide-
QD ratio (0 is control). Gel running conditions: 150 kV, 30 mins. (The anode is at the 
bottom of the figure). 
2.3.5 Optimisation of assay parameters 
Following the confirmation of the self-assembly of QD605 with p300 substrate 
peptide, it was possible to explore some of the parameters that could be adjusted to 
allow for detection of p300 HAT activity. 
The assay sensitivity is determined by a number of factors, including the selection of 
peptide to QD loading ratio, antibody-QD ratio, and temporal sequence of the assay. 
Figure 24 shows the typical spectral response after the QD605s have been 
functionalised with Ac-p300 peptide and subsequently treated with AF647 dye-
labelled anti-acetyllysine. The onset of a dye emission peak at 670 nm accompanied 
by a decrease in QD emission at 605 nm (as compared to a sample without antibody) 
is an indication that FRET coupling has occurred. This spectral change corresponds to 
a proximal binding of the antibody to the peptides immobilised on the QD surface; the 
covalently-linked dye molecules are now sufficiently close to induce FRET. 
Quantification of FRET is carried out by taking the ratio of the AF647 dye emission 
intensity to the QD605 photoluminescence (PL) intensity [18, 72].  
Different ratios of Ac-p300 peptide were loaded onto QD605s, with the resulting 
FRET ratios plotted in Figure 25. A trend towards increasing FRET at increasing 




Figure 24. PL emission spectra for Ac-p300 peptide-conjugated QD605s (peptide-QD 
ratio of 40:1) and incubated with (red line) AF647-labelled anti-acetyllysine antibody 
(antibody-QD ratio of 6.6:1); or (blue line) buffer only. 
number of antibody binding sites. The dependence of FRET signal on molar ratio of 
antibody to Ac-p300 peptide-conjugated QDs is shown in Figure 26. In the interests 
of conservation of material, molar ratios >20 were not investigated. The largest 
gradient in FRET ratio was found in the range 2.5-10 antibodies per QD, but 
saturation was not observed. The trend in the data mirrors closely that found by 
Nikiforov et al. [18] (see also Figure 27).  In the enzyme activity experiments that 
follow, it was decided to use a molar excess of dye-labelled antibody in the range 2.5-
10 antibodies per QD.  
The order of addition of assay components was subsequently analysed, particularly 
whether the p300 HAT should be added before or after peptide-QD conjugation. 
When the p300 HAT was added to pre-conjugated p300 substrate peptide-QD605s 
under assay conditions, there was no spectral change observed upon the introduction 
of AF647-labelled antibody. Figure 28 shows the relative sizes of the QD605, peptide 
substrate (assuming 0.35 nm per amino acid residue in an extended conformation), 
and p300 HAT (6 nm x 6 nm x 4 nm [22]). In this configuration, the binding of 
peptides in close proximity to the QD surface may not afford sufficient accessibility 




Figure 25. Ratio of PL intensities at 670 nm and 605 nm plotted against molar ratio of 
Ac-p300 peptide to QD605s after incubation with AF647-labelled anti-acetyllysine 
antibody (antibody:QD ratio of 6.6:1; dye-antibody loading ratio of 1.6:1). 
 
Figure 26. Ratio of PL intensities at 670 nm and 605 nm plotted against molar ratio of 
AF647-labelled anti-acetyllysine antibody to QD605s. (QDs functionalised with Ac-
p300 peptide at a peptide:QD ratio of 50:1; antibodies loaded with a dye-antibody 




Figure 27. FRET response of AF647-labelled anti-biotin bound to biotin-
functionalised QD605 at different molar ratios. Blue circles – ratio of PL intensities at 
605 nm and 670 nm; black squares – ratio of PL intensities at 670 nm and 605 nm. 
Note that the onset of saturation differs depending on the ratio used. Data replotted 
from Nikiforov et al. 
 
Figure 28. Scale drawing of p300 substrate peptide conjugated to a QD (note the six 
histidine residues coordinated to the QD surface), indicating possible binding 
positions of p300 HAT (dashed line). Position A – p300 binds to acetyllysine (marked 
in red) and 5 terminal residues; B – p300 binds entire peptide sequence; C – p300 
binds entire peptide sequence barring the 5 terminal residues.  
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by the p300 substrate peptide. Conceptually, this can be understood by considering 
the extent of the peptide sequence recognised and bound by the enzyme – e.g. in 
position A, the enzyme would be able to act on the substrate, whereas in position C, 
with more residues recognised, the enzyme is sterically prevented from binding the 
substrate. 
In light of this, the alternative assay format of incubation of p300 HAT with free p300 
substrate peptide was investigated. This approach has a number of potential 
advantages, including improved p300 HAT accessibility; and also the removal of 
considerations relating to the effect of substrate presentation and NP-enzyme 
interactions on enzyme activity, both arising due to the immobilisation of p300 
substrates close to the QD surface.  
Using this approach, the final parameter that was then investigated was the antibody-
antigen binding response. p300 peptide substrate was incubated with a high 
concentration of p300 HAT (640 nM), and then allowed to self-assemble with the 
QD605s for 1 h. Figure 29 shows the temporal response of the system after addition 
of AF647-labelled antibody. The FRET signal only begins to increase above the 
 
Figure 29. Ratio of PL intensities at 670 nm and 605 nm plotted against time since 
addition of AF647-labelled anti-acetyllysine antibody to QD605s (antibody-QD ratio 
of 6:1). QDs functionalised with p300 peptides (peptide:QD ratio of 50:1) which had 
been incubated with (black squares) 640 nM p300 HAT; or (white squares) buffer 
only. (Time 0 indicates the start of measurements, which includes the mixing and 
sample transfer time). 
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baseline (white squares) after the introduction of the developing agent i.e. the AF647-
labelled antibody, and only when the p300 HAT is present (the difference in signal at 
time 0 is due to the mixing and sample transfer time). This indicates that it is the 
biorecognition of the acetylation event, rather than an adsorption of the p300 HAT to 
the QD or optical change due to peptide binding that is the cause of the FRET signal. 
There was no non-specific binding observed between the antibody and the QD, as the 
baseline does not shift. The temporal response of the immunospecific interaction 
indicates that the binding sites are saturated within a period of 30-60 minutes, and so 
the antibody-QD incubation time was set to 1 h for all further experiments. 
 
2.3.6 Determining the dynamic range of the p300 assay 
The assay sensitivity was investigated by titrating the p300 HAT concentration in the 
range 0.1 – 200 nM, with an enzyme-peptide incubation time of 2 h. The resulting 
change in FRET signal is plotted in Figure 30. The signal begins to rise above 
baseline levels at a p300 HAT concentration >10 nM, and continues to rise at higher 
enzyme concentrations. It was not possible to reach saturation of the FRET signal in 
this titration due to limited quantities of p300 HAT available. However, the lower 
LOD was probed by increasing the enzyme-peptide incubation time from 2 h to 6 h 
(Figure 31). A small range of p300 HAT concentrations corresponding to the limit of 
sensitivity of existing radiolabelling assays [48] was selected. At these lower p300 
concentrations, it was possible to prepare larger enzyme reaction samples and the 
error bars in Figure 31 represent aliquots of peptide-enzyme sample probed with 
separate preparations of QD605s and AF647-labelled antibody. The error bars thus 
take into account inter-well variations in instrument readings. The LOD was defined 
as the concentration at which the FRET signal was greater than the control signal + 2 
times the error on the control. For this system, the LOD was determined as 0.5 nM, 
which is comparable with the established radioisotope-based techniques [48].  
In order to demonstrate the activity-based nature of this assay, the evolution of the 
enzyme-dependent signal with respect to time was investigated. Figure 32 shows the 
spectral response when aliquots of the p300 HAT-substrate peptide reaction mixture 
were assayed at 15-minute intervals. In panel A, the temporal evolution of the 
individual spectral peaks is plotted. The increase in AF647 emission at 670 nm occurs 




Figure 30. Ratio of PL intensities at 670 nm and 605 nm plotted against concentration 
of p300, showing an elevated response for [p300] > 10 nM. (p300+p300 substrate 
peptide incubation time of 2 h; peptide:QD ratio of 160:1; antibody:QD ratio of 
7.5:1).  
 
Figure 31. Ratio of PL intensities at 670 nm and 605 nm plotted against concentration 
of p300. Asterisk indicates limit of detection. (p300+p300 substrate peptide 




Figure 32. Spectral response of detection system at 15 min intervals after addition of 
320 nM p300 HAT. A - Peak PL intensity at 605 nm (QD605 response) and at 670 nm 
(AF647 response) plotted against incubation time of p300 substrate peptide with p300 
HAT. B – Ratio of peak intensities at 670 nm and 605 nm plotted at the same time 
points. Linear fit to initial rate increase used to calculate specific activity of enzyme. 
(p300 substrate peptide added at a peptide-QD ratio of 420:1; AF647-labelled anti-
acetyllysine added at an antibody-QD ratio of 6.4:1). 
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FRET between the QD605 and AF647 dye. In panel B, the ratio of the two peaks (I670 
nm/I605 nm) is plotted as a function of time; the increase in FRET signal corresponds to 
a rate of substrate conversion. Assuming that the saturation signal corresponds to a 
100% conversion of substrate (1 nmol), then the conversion rate is 0.0158 nmol/min. 
The amount of enzyme added was 0.00159 mg, thus the specific activity this batch of 
p300 HAT is calculated as 9.9 nmol/min/mg total protein. This is compared to 3.0 
nmol/min/mg quoted by the manufacturer (via radioisotope method). The discrepancy 
may be due to the signal saturation being caused by full occupation of antibody 
binding sites prior to exhaustion of substrate. This could be overcome by performing a 
calibration curve with Ac-p300 peptide. It would be possible to tune the dynamic 
range of the assay by adjusting the enzyme incubation time – LOD and saturation of 
the signal would occur at different concentrations depending on the extent of 
acetylation.  
Having determined that the assay was sensitive to the activity of p300 HAT, it was 
desired to test the ability of the assay to provide quantitative information about the 
inhibition of enzyme activity. To this end, a broad-spectrum HAT inhibitor, anacardic 
 
Figure 33. Ratio of PL intensities at 670 nm and 605 nm plotted against concentration 
of anacardic acid co-incubated with 250 nM p300 HAT and p300 substrate peptide. 
(Peptide-QD ratio of 235:1; AF647-labelled anti-acetyllysine added at an antibody-
QD ratio of 7.9:1). Fitted curve is a 4-parameter logistic plot. Error bars represent the 
standard deviation between two independent measurements. 
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acid [36] was co-incubated at varying concentrations with p300 HAT and p300 
substrate peptide during the acetylation step of the assay. Figure 33 shows the 
resulting FRET signal and dose-response curve fitted to the data. The expected 
behaviour of the inhibitor with respect to enzyme activity was observed, with FRET 
signal depressed at high anacardic acid concentrations. To quantify the inhibitor 
potency, the IC50 value (inhibitor concentration which provides a inhibition of signal 
corresponding to 50% of the full response range) was calculated and found to be 
59±12 µM, which is within a factor of seven of the published IC50 of 8.5 µM as 
determined by isotope labelling [102]. Although this was not tested, the resolution of 
the assay should be sufficient to allow for comparisons between different inhibitor 
molecules to be made. In terms of enzyme activity, it is clear that a constant enzyme 
concentration does not give a monotonic response (as would be the case if the assay 
were simply measuring total protein concentration). In fact, anacardic acid is thought 
to inhibit binding of acetyl-CoA to the active site of HATs [37]; hence the data 
measured at high anacardic acid concentrations is representative of the situation where 
p300 HAT is present but with negligible activity. This control indicates that the assay 
is sensitive to changes in enzyme activity. 
  
2.3.7  Discussion 
This chapter describes the development of the first NP-based assay for HAT activity. 
The homogeneous format was highly sensitive and was demonstrated in an inhibitor 
screening format.  
The demonstration of p300 HAT detection validates the original hypothesis that the 
QD-based kinase assay developed by Ghadiali et al. [72] could be modified in a 
simple manner for the detection of a distinct family of enzymes. In contrast to the 
kinase assay, where the peptide substrates were bound to the QD surface prior to 
treatment with enzyme; in this assay, the enzyme was incubated with the substrate 
peptide prior to peptide-QD conjugation. Hence, this assay could be said to improve 
the chances of probing native enzyme-substrate interactions, since NP-bound peptides 
are unrepresentative of native enzyme substrates. For example, NP size, curvature, 
surface charge, and density of functionalisation can all significantly affect steric 
accessibility and enzyme kinetics [103]. In the case of free peptides, enzyme-NP 
interactions are no longer an issue and the readout should be more representative of 
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the in vivo enzyme activity. However, the two-step nature of the off-dot assay did 
mean that kinetic analysis of p300 HAT was cumbersome to perform. Nevertheless, 
this did not preclude the use of end-point data in an inhibitor-screening format.  
A fluorescently labelled peptide substrate was used by Wu et al. [104] to detect 
electrostatic changes in the local environment upon the HAT-mediated acetylation of 
proximal lysine residues. This approach produced only modest shifts in fluorescence 
in the presence of 250 nM p300 HAT, and furthermore the labelled peptide may not 
represent a generalisable detection strategy for more context-specific enzymes. One 
might argue that the terminal His tag present on all peptide substrates used in the QD-
based assay is a type of label that could affect enzyme activity. However, it is possible 
to engineer the peptide sequence to include a number of (e.g. glycine) residues to 
separate the functional regions of the sequence so that the His tag remains at a non-
interfering distance from the enzyme recognition sequence. An alternative, highly 
sensitive method for assessment of PTMs is via time-resolved FRET using lanthanide 
chelates. Dudek et al. [49] used terbium-labelled antibodies to detect p300-mediated 
PTMs on green fluorescent protein (GFP)-tagged p53 protein. In this case, the QDs 
act as acceptors of the long-lifetime lanthanide emission – this format has been shown 
to have high sensitivity; however the format lacks flexibility in that the emission 
wavelengths of lanthanide chelates are discrete, not tuneable in the same way that QD 
emissions can be varied. The sensitivity of this method is at a similar level to the p300 
LOD reported in this chapter; however the cost of terbium-labelled antibodies is far 
greater than that of AF dye-labelled antibodies. 
In essence, the transferase assay platform is generic in nature, and it would be 
possible to tailor the system for a different class of transferase enzyme simply by 
altering the enzyme recognition sequence and using an antibody specific against the 
relevant amino acid modification. As long as there is a published enzyme consensus 
sequence and a specific antibody available, this approach should be completely 
generalisable. For enzymes that recognise extended portions of protein backbone, or 
that are conformation-specific, an alternative approach would be to recombinantly 
express a His-tagged protein. Use of an entire protein could possibly hinder signal 
transduction, since FRET is a distance-dependent process (the Förster radius for the 
QD605/AF647 pair has been estimated as 7.2 nm [18]). A FRET relay strategy could 




Figure 34. FRET relay detection of enzyme activity. A His-tagged target protein is 
fluorescently labelled in a non-enzyme-specific region. In the presence of the target 
enzyme, protein modification in a specific region will occur (red shading). The 
modification will be detected via self-assembly of the protein on a QD, and addition 
of a dye-labelled antibody sensitive to the protein modification. The QD and Dye 1 
form a donor/acceptor pair which will have a specific spectral signature. If the target 
enzyme is active, the antibody will bind to the protein, forming a FRET pair between 
Dye 1 and Dye 2 (Dye 2 is spectrally separated from the QD emission). Thus, a 
secondary spectral shift will indicate enzyme activity. Note, due to the nature of 
FRET, Dye 1 must possess longer-wavelength emission than the QD, and Dye 2 must 
possess longer-wavelength emission than both Dye 1 and the QD.     
would be fluorescently tagged in a non-interacting region. Subsequent binding of the 
protein to the QD would induce FRET from the QD to the fluorescent tags. Secondly, 
dye-labelled antibodies would be introduced to recognise the enzyme-mediated PTM, 
which would form a FRET pair with the fluorescent tags on the protein, inducing an 
enzyme-dependent change in fluorescence emission of the secondary dye. This 
approach was demonstrated by Medintz and co-workers [15]. In one iteration of their 
FRET-based maltose assay a QD was decorated with MBP complexed with dye-
labelled cyclodextrin, which was weakly bound in the maltose binding pocket, and 
displaced upon the introduction of maltose molecules. The FRET response was 
mediated by a fluorescent tag covalently attached to the maltose binding protein, 
which relayed energy from the QD to the dye-labelled cyclodextrin. This system is 
analogous to using a fluorescent reporter on the enzyme protein substrate to relay 
FRET to a dye-labelled antibody, as described above. In this format, even large 
proteins could be assayed in a straightforward manner. 
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The QD-based assay could be easily performed, and did not require many 
intermediate purification steps. Many assays require pre-functionalisation of target 
ligands with NPs, and subsequent purification of the products before assembly and  
treatment with enzyme [105, 106]. The purification step removes excess ligand and 
may affect the equilibrium number of ligands per NP. Two populations of labelled 
NPs are often required. By contrast, QDs are functionalized with only one ligand, in a 
homogeneous assay, reducing the risk of ligand exchange between separate NP 
populations. Optical-based methods have been developed that rely on the detection of 
CoA-SH (the deacetylated cofactor of HATs – see Figure 18). These include: a 
coupled enzyme assay producing a change in absorbance spectrum due to reduction of 
nicotinamide adenine dinucleotide (NAD) in the presence of CoA-SH [107]; and a 
small-molecule-based assay that produces a fluorescent signal upon coupling of the 
CoA-SH thiol [108]. These assays can generate a continuous signal, allowing for 
better appreciation of enzyme kinetics, however the detection method does not 
account for generation of CoA-SH by a non-specific process such as off-target 
enzymatic acetylation. The advantage of a peptide-mediated assay is that the sequence 
can be tailored to a specific enzyme, ensuring that the signal generated is relevant to 
the target of interest. Poveda et al. [48] described a radioisotope-based assay for HAT 
activity (the highest-sensitivity assays tend to be radioactivity based). The lowest 
HAT concentration observed was 1.5 nM, compared with 0.5 nM for the QD-based 
assay, which demonstrates that the QD assay is at the very least competitive with state 
of the art methods. In terms of high-throughput inhibitor screens, there are a few 
examples of Au NP-based assays which have been used for determination of enzyme 
inhibitor potency [109-111]. Up to 7 inhibitors were tested by Xu et al. [109], but 
only Oishi et al. [110] published IC50 values with good agreement with literature 
values. By integrating microfluidics with QD-based assays, it has been possible to 
develop high-throughput diagnostic devices [112], and this kind of technology could 
pave the way for a truly automated and commercially-viable small molecule drug 
screening platform.  
One drawback of the QD-based assay is the decreasing stability of NPs in the 
presence of biological molecules or high salt concentrations. This can be overcome to 
some extent by judicious selection of peptide sequence. For example, it is possible to 
prepare highly stable Au NPs by including a CALNN motif at the NP-binding 




Figure 35. Stability assay for QD605s with respect to human serum albumin (HSA) 
and bovine serum albumin (BSA) concentration. Peak photoluminescence plotted for 
each condition. n=4. 
Au NP surface; this would be replaced with a His tag for QD applications), AL 
(hydrophobic, self-assembly of a core-shielding monolayer) and NN (hydrophilic, 
dispersion in aqueous media). The introduction of large protein molecules such as 
BSA can also improve the stability of NP dispersions. It is postulated that BSA can 
form a layer with extended conformation at the surface of NPs that affords them 
enhanced stability [114]. It is not clear whether other proteins have a similar 
beneficial effect; preliminary experiments were carried out to assess the stability of 
QDs in the presence of human serum albumin (HSA). Figure 35 shows that the PL of 
QD605s was enhanced in the presence of 0.01% w/v BSA, while the addition of 
human serum albumin (HSA) did not significantly affect the emission. This change in 
PL emission suggests that the BSA is capable of interacting with the QD surface, 
which may afford them greater stability in harsh biological environments. 
 
2.4 Conclusions and Outlook 
A QD-based HAT activity assay was demonstrated. Characterisation of the individual 
assay components was carried out; p300 HAT was shown to recognise and acetylate 
the synthetic p300 substrate peptide in solution; and the acetylated peptides were 
successfully coupled to the QD surface via metal-affinity coordination. Acetylation of 
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lysine residues was specifically detected by means of immunocomplex formation with 
AF647-labelled anti-acetyllysine antibody and generation of a FRET signal. The assay 
was shown to be sensitive at nM enzyme concentrations, with a LOD of 0.5 nM. 
Controls indicated that the assay was sensitive to the activity of p300 HAT. The assay 
was subsequently used to determine the potency of a small-molecule HAT inhibitor, 
and the specific activity of p300 HAT was quantified. 
A further validation of the assay utility would be to differentiate between mutated 
forms of the same enzyme with different activities. For example, p300 has been 
shown to have a regulatory role in the suppression of cancers [28]. In respect of this 
study, it would be of interest to compare the activity of HATs in different tumour 
samples (normalised by enzyme concentration, determined by ELISA), in parallel 
with genomic data, to determine the effect of mutations that do not completely destroy 
HAT activity. CREB binding protein (CBP), which possesses HAT activity, has been 
shown to have a crucial role in memory formation. Mutations in the gene for CBP can 
cause Rubinstein-Taybi Syndrome (symptoms include learning difficulties and 
increased risk of some cancers), due to decreased enzyme activity [115]. It may be 
possible to treat such diseases using activators of HAT activity [116], and the search 
for such molecules could be performed in a high-throughput manner using the HAT 
assay described in this chapter.  
In terms of drug discovery, the antagonistic complement to HATs, histone 
deacetylases (HDACs) have been the target of anti-cancer drugs [117]. The assay 
could be modified to use chemically-acetylated peptides as substrates for HDACs in a 
high-throughput format; our group has had discussions with the Imperial Drug 











3 Detection of serine phosphorylation 
3.1 Introduction 
In this chapter, strategies for the detection of serine phosphorylation are described. 
This PTM is relevant in that the mechanism of serine phosphorylation shares a 
number of features with that of acetylation (described in Section 1.3.1) and with 
tyrosine phosphorylation. The serine kinase-mediated phosphorylation reaction is 
shown in Figure 36. The serine kinase facilitates the transfer of the γ-phosphate from 
ATP (the enzyme cofactor) to serine residues within the enzyme recognition site of 
the substrate, leaving ADP as a by-product. 
Aberrant activity of protein kinases has been implicated in a number of diseases 
including cancers, arthritis and neurodegeneration, and hence present an attractive 
target for drugs combatting these conditions [34]. The serine kinase cyclic guanosine 
monophosphate-dependent protein kinase (PKG), by contrast, has been found to 
regulate the life cycle of the malaria parasite Plasmodium falciparum, and hence is a 
target for drugs preventing the maturation of parasites. The research group of Dr. 
David Baker at the London School of Hygiene and Tropical Medicine (LSHTM) has 
tested the effect of various inhibitory compounds on the activity of P. falciparum-
derived PKG, using a scintillation-based method [118]. 
 
Figure 36. Serine kinase reaction scheme. Serines within the enzyme recognition 
sequence are phosphorylated in the presence of serine kinases and ATP. Inset – 
structure of ATP. 
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The activity-dependent detection of kinases using a QD-based platform has been 
demonstrated by Ghadiali et al. [72] and Freeman et al. [73], with the latter achieving 
the detection of casein kinase (a serine kinase). It was decided to form a collaboration 
with the Baker group at LSHTM in order to systematically compare the QD-based 
assay with a commercial alternative, and calibrate the sensor via its inhibitor-
dependent response. 
As in Chapter 2 and publications [72, 73], it was decided to use antibodies to 
recognise the kinase-mediated phosphorylation of serine residues. However, while 
high-affinity anti-phosphotyrosine antibodies are prevalent [41, 119], high-affinity 
analogues for anti-phosphoserine and anti-phosphothreonine have yet to be 
developed, except for context-dependent antibodies that are specific to 
phosphorylated residues within particular amino acid sequences [120]. The absence of 
highly-specific antibodies may reflect the lower immunogenicity of phosphoserine 
and phosphothreonine relative to phosphotyrosine in vivo [121]. Bearing this in mind, 
alternative serine kinase detection strategies were considered in parallel with the 
antibody-based detection. Figure 37 illustrates the possible detection methods and 
controls investigated in this chapter. Figure 37A denotes the detection of 
phosphoserine (black circle) by means of dye-labelled anti-phosphoserine. Figure 37B 
illustrates detection of kinase activity via SA-biotin interactions. In this approach,  
 
Figure 37. Summary of alternative detection methods and controls. A. Direct 
detection of serine phosphorylation via dye-labelled anti-phosphoserine antibodies. B. 
Detection of serine phosphorylation using biotinylated γ-ATP. Dye-labelled SA can 
subsequently induce FRET. C. biotin-labelled QD used as a control to investigate the 
binding of dye-labelled SA. 
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biotin-labelled ATP would be used so that the phosphorylation reaction would also 
result in biotinylation of the substrate. The phosphorylation-biotinylation event would 
then be detected by means of dye-labelled SA molecules. A Au NP-based platform for 
the detection of serine kinases via the introduction of biotin-labelled ATP was 
demonstrated by Wang et al. [62]. Finally, Figure 37C indicates a control system that 
could be prepared to test the applicability of the SA-biotin detection system, where 
the biotin would be covalently attached to the passivating MPA ligands coating the 
QD surface.  
The choice of the SA-biotin pair was determined by the high affinity of the 
interaction, with a dissociation constant of ~ 10-14
 
M [122]. One drawback of using 
this pairing is the requirement to use labelled ATP, with the potential for binding of 
free biotin-ATP by SA to decrease the sensitivity of the assay.  
 
3.1.1 Scope of Chapter 
In this chapter, a number of formats for the detection of enzyme-mediated serine 
phosphorylation are explored, including antibody-based and SA-biotin-based assays. 
It was necessary to consider and construct appropriate controls to assess the 
specificity of respective biomolecular interactions. 
 
3.2 Materials and methods 
3.2.1 Materials 
CdSe/ZnS core-shell QDs (1 µM in decane) with a nominal emission wavelength of 
605 nm (QD605) and AlexaFluor 647 carboxylic acid, succinimidyl ester, (AF647-
NHS) were purchased from Life Technologies (Paisley, UK). Mouse monoclonal anti-
phosphoserine IgG antibody, clone PSR-45 (2 mg/mL in 15 mM sodium azide/PBS 
solution) was purchased from Sigma-Aldrich (Gillingham, UK).  Mouse monoclonal 
anti-phosphoserine IgG antibody, clone 3C171 (2.6 mg/mL in 0.05% w/v sodium 
azide/PBS solution with 15 mg/mL BSA) was purchased from Abcam (Cambridge, 
UK). Mouse monoclonal anti-phosphoserine IgM antibody, clone 16B4 (0.1 mg/mL 
in 15 mM sodium azide/PBS solution) was purchased from Santa Cruz Biotechnology 
(CA, USA). EZ-Link Pentylamine-Biotin and 1-ethyl-3-(3-dimethylaminopropyl) 
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carbodiimide (EDC) were purchased from Fisher Scientific (Loughborough, UK). N-
Hydroxysuccinimide (NHS) was purchased from Sigma-Aldrich (Gillingham, UK). 
Streptavidin, AlexaFluor 647 conjugate (SA-AF647) was purchased from Life 
Technologies (Paisley, UK). 
 
3.2.2 Peptides 
3.2.2.1 Peptide design 
The PKG phosphorylation sequence was recommended by researchers at LSHTM, 
with the enzyme recognition sequence given by RTGRRN(S)*I (preferred site of 
phosphorylation indicated by an asterisk). No spacer was included because of 
concerns about binding distance of the antibody from the QD.  
 
3.2.2.2 Peptide synthesis 
The following peptide was synthesised using a Symphony Quartet peptide synthesiser 
(Protein Technologies Inc., Arizona, USA). 
PKG substrate peptide:  
HHHHHHRTGRRNSI-NH2 
Predicted MW: 1781.0 Da 
 
The following peptide was purchased from LifeTein LLC (New Jersey, USA).  
pS-PKG peptide:  
HHHHHHRTGRRN(pS)I-NH2 
Predicted MW: 1861.0 Da Purity: 88% 
 
3.2.3 Preparation of bioconjugates 
3.2.3.1 Dye-Antibody conjugation 
AF647-NHS dye was conjugated to each of the anti-phosphoserine antibodies, 
following the manufacturer’s instructions. See Section 2.2.4.1 for further details and 




3.2.3.2 Conjugation of peptides to QDs 
Peptides were conjugated to QDs via His tag-metal coordination, a self-assembly 
process, as described in Section 2.2.4.2. 
 
3.2.4 UV/Visible absorbance spectroscopy and fluorimetry 
UV/Visible absorbance spectroscopy was carried out using a NanoDrop 2000c with 
cuvette capability (Thermo Scientific, Delaware, USA) and quartz cuvettes (Hellma 
Analytics, Müllheim, Germany). The extinction coefficients in Table 4 were used to 
determine the concentrations of the NPs and biomolecules used in this chapter. 
Fluorescence spectra were recorded in the spectrophotometer mode using a 
SpectraMax M5 microplate reader with an excitation wavelength 405 nm and cutoff 
filter at 435 nm. 
Molecule ε(280 nm) / M-1cm-1 ε(650 nm) / M-1cm-1 
AF647 dye 7,170 239,000 
IgG antibody 203,000 negligible 
Table 4: Molar extinction coefficients for molecular species used in this chapter. 
















3.3 Results and discussion 
3.3.1 Peptide synthesis 
PKG substrate peptide was analysed by MALDI mass spectrometry. Figure 38 
indicates the mass spectrum for PKG substrate peptide, with a peak indicating the 
expected MW of 1780 Da. 
 
Figure 38. MALDI mass spectral analysis of PKG substrate peptide. A. Chemical 
structure of PKG substrate peptide. B. MALDI mass spectrum for PKG substrate 
peptide, with the labelled ionisation peak (P+H+) indicating a peptide molecular 
weight of 1780 Da. The matrix used was alpha-cyano 4-hydroxy cinnamic acid.  
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3.3.2 Bioconjugation of antibodies with AF dye 
The sensing component of the assay is based on the specificity of monoclonal 
antibodies against phosphorylated serine residues. In order to effect a FRET-mediated 
spectral response upon formation of the QD-peptide-antibody complex, the antibodies 
were labelled with FRET acceptor dye molecules. 
Table 5 summarises the antibodies used in this Chapter, with the final antibody and 
dye concentrations determined after purification via spin desalting column.  
Two different IgG clones (PSR-45 and 3C171) and one IgM clone (16B4) were 
labelled with AF647-NHS dye, with the dye covalently linking to free amines within 
the antibody. A range of apparent labelling ratios were observed, with dye:antibody 
ratios ranging from 1:1 to 10:1. 
The IgM clone 16B4 was supplied at a lower concentration than the IgG clones, and 
despite the apparent labelling ratio of 10:1, was found to be unsuitable for the 






Dye Concentration (µM) 
PSR-45 (Abcam) AF647 12.3 39 
PSR-45 (Sigma) AF647 4.6 35 
3C171 (Abcam) AF647 6.4 7.9 
16B4 (Santa Cruz) AF647 0.15 1.6 
Table 5: Absorbance of dye-antibody conjugates, measured by UV/Visible 
spectrometry. The concentrations were determined using the molar extinction 
coefficients listed in Table 2.  
 
3.3.3 Detection of phosphoserine via antibody immunorecognition 
In this section, positive controls utilising pS-PKG peptide and negative controls 
utilising PKG substrate peptide are described. These experiments tested the assay 
response to varying concentrations of phosphopeptide. Antibody specificity was 
compared using the antibodies listed in Table 5. 
The effect of changing the concentration of pS-PKG peptide whilst maintaining a 
constant QD605 concentration was investigated by altering the ratio of pS-PKG : 
PKG substrate peptide at constant total peptide:QD ratio. The results of incubating 
each sample with two different preparations of AF647-labelled anti-phosphoserine are 
shown in Figure 39. In the case of the antibody clone PSR-45 (Abcam), there is a 




Figure 39. Comparison of FRET responses for differing proportions of positive 
control (PKG-pS) to PKG substrate peptides. Ratio of PL intensities at 670 nm and 
605 nm, plotted against percentage of phosphorylated peptides. (Peptide:QD ratio of 
200:1; antibody:QD ratio of 8:1).  
For the antibody clone PSR-45 (Sigma), the same trend is apparent for samples where 
the proportion of pS-PKG peptide was >40%. The lowest signal observed was for the 
100% pS-PKG peptide sample. As was the case for the p300 HAT assay in Section 
2.3.5, the signal would be expected to increase with increasing amounts of positive 
control (pS-PKG) peptide. However, the opposite effect was observed, with the 
highest concentration of pS-PKG actually generating the lowest signal. 
In order to elucidate the origin of this reverse trend, samples containing either PKG 
substrate peptide or pS-PKG peptide were prepared, at different peptide:QD ratios. 
Figure 40 shows the spectral response of QD605s incubated with a range of PKG 
substrate peptide concentrations, followed by addition of AF647-labelled anti-
phosphoserine antibody (PSR-45, Abcam). Decreases in I605 nm were associated with 
increases in I670 nm, with greater changes observed as the peptide:QD ratio was 
increased from 25:1 to 400:1. Figure 41 shows data from the same experiment plotted 
as the ratio of I670 nm / I605 nm, including also data from experiments where pS-PKG 




Figure 40. PL emission spectra for QD605s functionalised with PKG substrate peptide 
and incubated with AF647-labelled anti-phosphoserine. The different colours indicate 
different molar ratios of peptide:QDs.  
 
Figure 41. Comparison of FRET responses for positive control (PKG-pS) and PKG 
substrate peptides. Ratio of PL intensities at 670 nm and 605 nm, plotted against 
molar ratio of peptide:QD. Squares – PKG substrate peptide; triangles – PKG-pS 




Figure 42. Comparison of FRET responses for positive control (PKG-pS) and PKG 
substrate peptides. Ratio of PL intensities at 670 nm and 605 nm, plotted against 
molar ratio of peptide:QD. Squares – PKG substrate peptide; triangles – PKG-pS 
peptide. Antibody 3C171 (Abcam) added at an antibody:QD ratio of 13:1. 
irrespective of peptide phosphorylation. In fact, the response with respect to PKG 
substrate concentration (unphosphorylated) is higher than that for the phosphorylated 
peptide. This explains the trend observed in Figure 39, since decreasing the proportion 
of phosphorylated peptide would actually increase the observed FRET. 
Bearing in mind that anti-phosphoserine antibodies can sometimes suffer from lack of 
specificity in cases where the correct amino acid context is not present, it was decided 
to repeat the experiment shown in Figure 41, using a different antibody clone (3C171, 
Abcam). The results of this experiment are shown in Figure 42; a similar trend, with 
no specificity for phosphorylated residues, was observed. 
In response to the lack of antibody specificity observed, an alternative detection 




3.3.4 Streptavidin-biotin-based detection of peptide modification 
The experiments described in this section were carried out to determine the feasibility 
of using a biotin-SA-based detection system for peptide phosphorylation (see Figure 
37B).  
In order to investigate the role of non-specific interactions between antibodies/SA and 
the QD surface, unmodified QD605s were incubated with either AF647-labelled anti-
phosphoserine antibodies or AF647-labelled SA. The spectral responses, compared 
with the control QD sample, are shown in Figure 43. A characteristic FRET response 
is seen for both the AF647-labelled anti-phosphoserine antibodies and the AF647-
labelled SA, but is more pronounced for the antibody samples. This suggested that the 
SA system might prove more robust against the non-specific binding described in 
Section 3.3.3.  
Control samples to probe the biotin-SA interaction were prepared. Biotin was 
covalently coupled to the MPA coating of QD605s, using EDC/NHS coupling [101]. 
Control samples without biotin were also prepared. Figure 44 shows the spectral peak 
response after the addition of varying amounts of AF647-SA. The QD response (blue 
data points) shows a sharp fall in PL upon the coupling of biotin. In terms of the dye 
response (black data points), the addition of higher concentrations of SA increases the 
 
Figure 43. PL emission spectra for MPA-coated QD605s (circles) incubated with 





Figure 44. Direct coupling of varying amounts of biotin to QD605s and probing with 
AF647-labelled streptavidin. Peak PL intensity at 670 nm (black data points) and at 
605 nm (blue data points) plotted against ratio of biotin:QDs. Squares – 16:1 
streptavidin:QD ratio; triangles – 8:1 streptavidin:QD ratio. 
dye emission. This is due to higher concentrations of dye present, and not a specific 
binding event, since there is negligible increase in the emission intensity with an 
increase in biotin labelling of the QDs. From the QD emission, it can be seen that the 
covalent coupling of biotin decreases the QD PL, perhaps due to neutralisation of 
electrostatic charge at the QD surface. The response upon addition of SA suggests that 
little or no specific binding occurred. This may be due to steric effects preventing the 
SA from approaching close to the surface of the QDs. The control signal for 
unlabelled QDs is consistent with the data shown in Figure 43. 
 
3.3.5 Discussion 
The results in Section 3.3.3 indicate a lack of specificity of anti-phosphoserine 
residues in this system. In a similar system, published by Freeman et al. [73], no such 
non-specificity was observed. 
Possible explanations for the observed effects include the influence of surrounding 
amino acid residues which can help to confer specificity for phosphoserine [120]. The 
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PKG substrate sequence selected may not contain residues that favour specific 
recognition, alternatively, it may contain residues that disfavour the specific 
interaction between the antibody and the antiphosphoserine residue. A systematic 
search for PKG substrates (using peptide libraries and peptide array technologies) 
might yield peptide sequences affording a greater degree of antibody specificity. This 
approach might benefit from the judicious selection of context-specific antibodies that 
recognise extended amino acid sequences. Enzyme recognition sequence 
determination was beyond the scope of this project, and time constraints precluded the 
use of context-specific antibodies. Hence, alternative detection modalities were 
investigated.  
In Section 1.4.1, trivalent metal ions used to detect phosphorylation were described; 
these were considered as an alternative detection strategy. As of October 2011, the 
manufacturers of these reagents were no longer supplying the products, and hence it 
was not possible to investigate the use of these molecules in a QD-based detection 
format. 
The preliminary results in Section 3.3.4 illustrate the importance of developing 
representative controls for analysis of the SA-biotin detection methodology. The 
effect of directly coupling the amino-biotin labelling molecule to the QD surface was 
to decrease the QD PL without exhibiting any subsequent binding of AF647-SA. A 
more representative control would be to conjugate the amino-biotin label to a 
modified peptide substrate via EDC/NHS coupling. A suitable modified sequence 
might be: HHHHHHRTGRRNDI-NH2, where the serine residue has been replaced by 
an aspartic acid containing a carboxyl group. After the coupling reaction, the amino-
biotin would be expected to attach to the aspartic acid residue. This mimics the 
situation shown in Figure 37B, where the enzyme activity mediates the transfer of a 
biotin-labelled phosphate group from biotin-ATP to the serine residue present in the 
PKG substrate. Due to time constraints, it was not possible to synthesize the relevant 
peptide control. Here, a number of potential issues arising from the use of SA-biotin 
interactions are discussed. 
As was discussed in Section 1.4.1 concerning the use of trivalent metal ions which 
bind to phosphate groups, use of such reagents can affect the assay in a number of 
ways. Firstly, the reagents will bind to ATP, since they are not specific towards 
phosphorylated amino acids alone; this means that the assay will not be effective at 
high ATP concentrations. Secondly, phosphorylation of residues other than the target 
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will be detected via these reagents. When using biotin-labelled ATP, similar concerns 
arise; SA will bind the ATP as well as the enzymatically-modified peptide substrate; 
any other biotinylated molecule can act as a site for SA binding. Both these issues will 
contribute to a decrease in signal intensity and specificity. A third factor that arises 
due to the use of SA is that of multivalency, in particular the potential for cross-
linking of QDs (as illustrated in Figure 45). It would be possible for the SA to bridge 
neighbouring QDs via biotin binding, resulting in NP aggregation and precipitation, or 
affecting the QD PL. In the study of Wang et al. [62], the aggregation of Au NPs in 
response to kinase activity was demonstrated using a SA-biotin binding strategy, 
however in this case, NP aggregation was a desired effect, providing a high-sensitivity 
response, illustrated in  Figure 11. The aggregation of QDs would not provide a high 
level of sensitivity, and assemblies of QDs are not used in the literature as a sensing 
mechanism.  
 
Figure 45. QDs crosslinked by streptavidin-biotin interaction. This figure illustrates 
the situation where QDs have been functionalised with biotin-labelled peptides and 
incubated with streptavidin. Streptavidin contains 4 biotin binding sites, and hence has 




3.4 Conclusions and Outlook 
Assays to detect phosphorylation of serine residues were designed. The assay utilising 
dye-labelled antibodies as the sensing component did not exhibit specificity towards 
the phosphorylated form of the peptide. An alternative detection modality, utilising 
SA-biotin affinity, was investigated. It was not possible to fully characterise the 
interactions in the system due to the absence of an appropriate control peptide, 
however the degree of non-specific interaction between MPA-capped QDs was 
greater for the dye-labelled antibodies than for the dye-labelled SA. 
In this thesis, a generic QD-based assay for enzyme PTMs has been described. The 
detection of lysine acetylation was demonstrated in Chapter 2, and the detection of 
tyrosine phosphorylation was reported by Ghadiali et al. [72]. The detection of 
phosphoserine represents a limitation of the assay, because of the difficulty in 
obtaining high-affinity antibodies against this modification. The work of Freeman et 
al. [73] suggests that detection can be achieved in some cases, but the antibodies used 
have been found not to be universally specific. A further potential avenue lies in the 
development of specific ribonucleopeptide binding complements for amino acid 
residues [123, 124]. However, as yet, serine/phosphoserine specificity has not been 
demonstrated.   
Despite the issues encountered with this detection system, the target disease, malaria, 
still remains a pressing clinical priority. In Africa, 16% of deaths of infants under 5 
years old are due to malaria [125]. Malaria is a treatable disease, however, there is an 
increasing problem of resistance to artemisinin, the major drug used in combating the 
disease (in some regions, the resistance level is >10% [126]). Hence, it is of critical 
importance to develop new malaria drugs and rapid diagnostic tests in order to stay 
one step ahead of the disease. Given the resources to determine antibody-recognisable 
enzyme substrates, the QD-based enzyme assay might still find an application as a 




4 Activity-dependent and multiplex assays for HER2 
kinase and uPA protease 
4.1 Introduction 
The bulk of NP-based assays for enzyme biomarkers (reviewed in Section 1.4.4) are 
designed for a specific analyte, or a single family of enzymes. The system described 
in this chapter expands on the work done previously, by attempting to simultaneously 
detect the activity of more than one family of enzyme, namely a kinase and a protease. 
The advantages of being able to simultaneously detect multiple analytes in the same 
sample (multiplexing) include higher throughput and assay speed; reduction of 
systematic errors due to the effect of inter-well variation to improve assay 
reproducibility [67]; and the improvement in predictive power that arises due to the 
quantification of more than one relevant marker. 
In terms of disease progression, biomarker profiling for breast cancer sufferers is of 
particular interest [127]. According to the WHO [125], over 0.5 million women die 
from the disease each year (2004 estimates), with breast cancers accounting for 16% 
of all cancers in women, making it one of the most common types of female cancer, 
after lung cancer. Mortality is affected by disease progression at diagnosis, metastatic 
potential, and cancer phenotype. The biomarker pair of HER2 kinase and uPA 
protease has been shown to provide significant prognostic information in terms of the 
metastasis-free survival of breast cancer patients [30], with clinical cutoffs for 
negative/positive prognosis of 400 fmol/mg protein for HER2 and 5.5 ng/mg protein 
for uPA, in pulverized biopsy samples. This translates to a desired assay sensitivity of 
15 nM for HER2 and 200 ng/mL for uPA [128]. The design of a multiplex assay for 
HER2 kinase and uPA protease (based on their enzymatic activity) has the potential to 
provide physicians with a powerful predictive tool for use in the clinical setting, and 
also serves as a proof-of-concept for this particular assay platform. 
Considering each enzyme in turn, HER2 kinase is a membrane-bound receptor 
tyrosine kinase. In vivo, activation is modulated by binding of growth factors; 
however it has been shown that the intracellular portion (containing the tyrosine 
kinase domain) retains its activity, even after the shedding of the extracellular domain 
[129]. The mechanism of action is illustrated in Figure 46, whereby the kinase 




Figure 46. Tyrosine kinase reaction scheme. Tyrosines within the enzyme recognition 
sequence are phosphorylated in the presence of kinase and ATP. Inset - structure of 
ATP. 
 
Figure 47. Serine protease reaction scheme. The peptide bond between serine and 
another amino acid within the enzyme recognition sequence is hydrolysed in the 
presence of proteases in aqueous buffer. 
tyrosine residues. HER2 has considerable significance in breast cancer therapy – it is 
overexpressed in over 20% of breast cancers [130], and increases the invasiveness of 
cancer cells [131-133]. HER2 is almost universally quantified upon diagnosis due to 
its indicative utility in predicting response to treatment with the anti-cancer drug 
trastuzumab [127]. 
uPA protease is a serine protease, facilitating hydrolysis of the peptide bond between 
two amino acids, one of which must be a serine (as illustrated in Figure 47). The 
overexpression of uPA has been linked to cancer invasiveness and metastasis, through 
increased activation of its substrate plasminogen to plasmin, which is a particularly 
destructive ECM-degrading protease. uPA is also thought to have a direct role in 
ECM degradation [134, 135]. 
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The challenges to be addressed in the development of this assay are the detection of 
two different enzyme families, and maintaining the independence of the enzyme-
specific signals. In terms of HER2 kinase detection, the relevant QD-based kinase 
assays have been reviewed extensively in Section 1.4.4.1. The kinase target, HER2, is 
commonly imaged in antibody-based immunohistochemistry (IHC) assays [136-140]. 
However, IHC requires the extraction and sectioning of biopsy samples prior to 
incubation with fluorescently-labelled antibody, with the resulting signal dependent 
only on HER2 concentration presented on the cell surface. By contrast, the QD-based 
method is relatively simple to perform and reports directly on the enzyme activity; 
hence assumptions about correlating enzyme concentrations to total activity are 
removed. In addition, there is some evidence that the extracellular domain of HER2 
can be shed [129], meaning that determining a prognosis based on cell-surface 
receptors alone may be misleading. Observing HER2 activity using the QD-based 
assay represents a further validation of the transferase detection assay. For the uPA 
protease, this chapter introduces a QD assay format for the detection of protease 
activity. This assay differs from the transferase assays previously mentioned in that 
the enzymatic modification is not detected via immunological recognition. Rather, the 
physical act of peptide bond cleavage is an effector of the measured signal change. A 
number of QD-based methods for protease detection have been reported, based on the 
dequenching of QD emission in the presence of a protease. Molecules used for the 
initial quenching of the QDs have ranged from Au NPs [76], to fluorescent dyes [70, 
141] and ruthenium complexes [78]. These methods were reviewed in Section 1.4.4. 
Multiplex assays present an added degree of complexity over single-analyte assays. 
Focusing on NP-based multiplexing, to achieve simultaneous readout from a single 
sample, the system must have the following properties: a) specificity towards the 
different analytes and; b) low cross-talk between the signals for separate analytes. A 
further desirable attribute for such a system would be the ability to assay clinical 
samples directly. In this chapter, each of these issues is addressed, describing the use 
of peptide substrates to ensure specificity; strategies for the decoupling of enzyme-
specific responses; considerations relating to the efficient use of the available spectral 
range; and investigations into the applicability of the assay format for the analysis of 
biological samples.  
A schematic of the multiplex assay is given in Figure 48. This figure illustrates some 




Figure 48. Multiplexed detection of uPA protease and HER2 kinase via an orthogonal 
coupling strategy. Peptide substrates are simultaneously incubated with uPA and 
HER2 enzymes. uPA mediates proteolytic cleavage of Au NP-labelled biotinylated 
substrate peptide (blue), while HER2 mediates phosphorylation of the HER2 substrate 
peptide (purple). Following enzyme incubation, a mixture of streptavidin-coated 
QD525s and MPA-coated QD655s is added, resulting in self-assembly of the 
structures A-D (only one peptide per quantum dot shown for clarity). A) Uncleaved 
uPA substrates form a QD525-peptide-Au NP complex via biotin-streptavidin 
interaction and QD525 emission is quenched. B) Cleavage of uPA substrate prevents 
Au NP binding and QD525 emission remains unquenched. C) and D)  His-tagged 
HER2 substrates bind to QD655 via metal-affinity coordination, however only when 
the substrate peptides are phosphorylated (D) does the introduction of dye-labelled 
anti-phosphotyrosine antibody lead to immunocomplex formation and FRET.   
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signal independence. Enzyme specificity is engineered by incorporating enzyme 
recognition motifs into the corresponding substrate peptide sequences. The intended 
response upon addition of the enzymes is shown at the top of Figure 48. Decoupling 
of the enzyme response would be achieved by either pre-immobilising the peptides on 
the QDs prior to treatment with enzyme (not shown), or by selecting peptide-QD pairs 
with mutually orthogonal coupling interactions. These strategies would segregate the 
different enzyme products on the surface of different QD populations. By using QDs 
with different emission maxima, this architecture is designed to allow the resolution 
of the signals from each enzyme at different regions of the fluorescence emission 
spectrum. 
 
4.1.1 Scope of Chapter 
This chapter concerns the development of a multiplexed assay for the activity-based 
detection of analytes from differing enzyme families. The assay structure was 
constructed based on two independent QD-based assays, one for the detection of 
HER2, a kinase, and the second for uPA, a protease. It was necessary to individually 
design and verify systems capable of detecting each of the enzymes separately, before 
attempting to combine them into an integrated format. In this chapter, only systems 
capable of probing mixed samples of enzymes were considered. The steps taken to 
minimise cross-reactivity between components of the individual assays are described, 
and an investigation of the merits of various substrate immobilisation strategies was 
carried out. 
 
4.2 Materials and Methods 
CdSe/ZnS core-shell QDs (1 µM in decane) with nominal emission wavelengths of 
565 nm (QD565) and 655 nm (QD655); SA-conjugated CdSe/ZnS core-shell ITK 
QDs (2 µM in aqueous buffer) with nominal emission wavelengths of 525 nm 
(QD525-SA) and 655 nm (QD655-SA); SA-conjugated poly(ethylene glycol) (PEG)-
linked CdSe/ZnS core-shell QDs (2 µM in aqueous buffer) with a nominal emission 
wavelength of 525 nm (QD525-PEG-SA); and AlexaFluor 660 carboxylic acid, 
succinimidyl ester, (AF660-NHS) were purchased from Life Technologies (Paisley, 
UK). Monomaleimido Nanogold (1.4 nm Au NPs functionalised with a single 
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maleimide group) was purchased from Nanoprobes (New York, USA). Mouse 
monoclonal anti-phosphotyrosine IgG antibody, clone PT-66 (2 mg/mL in 15 mM 
sodium azide, 0.01 M phosphate buffered saline, pH 7.4), ATP (disodium salt), 
HEPES buffer (99%), MgCl2 (98%), Tris(2-carboxyethyl) phosphine hydrochloride 




Recombinant human HER2 was purchased from SignalChem (British Colombia, 
Canada). It was aliquoted and stored at -80 ºC before use. Native uPA from human 
urine was purchased from Merck Chemicals (Nottingham, UK). It was aliquoted and 
stored at -20 ºC before use. 
HER2 storage buffer composition: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM 
glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM phenylmethylsulphonyl fluoride 
(PMSF), 25% v/v glycerol. 
uPA storage buffer composition: 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 200 mM 
mannitol, 0.1% w/v PEG. 
 
4.2.2 Peptides 
4.2.2.1 Peptide design 
In designing peptides for the multiplex assay, maintaining enzyme specificity and 
activity were the primary concerns. The HER2 substrate was determined from the 
kinase activity assays of Kerman [142] and others, with the consensus recognition 
sequence given by DNEY*FYV (preferred site of phosphorylation indicated by an 
asterisk). As was described for the p300 HAT assay in Section 2.2.3.1, an N-terminal 
His tag and GGG spacer were added for attachment of the substrate to the QD surface 
and to facilitate access to the enzyme modification site. 
The uPA substrate was determined by phage display studies carried out by Ke et al. 
[143], where the consensus cleavage sequence is given as SGR↓SANAI (proteolysis 
site indicated by an arrow). In this case, an extra Cys residue was added at the C 
terminus, to facilitate binding to an Au NP. The N terminus was used for binding to 
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QDs; the binding motif was a His tag when MPA-coated QDs were used and biotin 
when a SA-coated QD was used. 
4.2.2.2 Peptide synthesis 
The following peptides were synthesised using a Symphony Quartet peptide 
synthesiser (Protein Technologies Inc., Arizona, USA). 
HER2 substrate peptide: HHHHHHGGGDNEYFYV-NH2 (C-terminal amidation) 
Predicted MW: 1942.0 Da 
 
His-tagged uPA substrate peptide: HHHHHHGGGSGRSANAIC-NH2  
Predicted MW: 1871.0 Da 
 
The following peptides were purchased from LifeTein LLC (New Jersey, USA).  
pY-HER2 peptide: HHHHHHGGGDNE(pY)FYV-NH2  
Predicted MW: 2022.0 Da Purity: 85% 
 
Biotinylated uPA substrate peptide: biotin-SGRSANC-NH2  
Predicted MW: 919.1 Da Purity: 98% 
(For this peptide, the -AI- motif was removed to increase proximity of the Au NPs 
and QDs) 
 
4.2.3 Preparation of bioconjugates 
4.2.3.1 Dye-Antibody conjugation 
The AF660-NHS dye was conjugated to the anti-phosphotyrosine antibody as per the 
manufacturer’s instructions (10-fold molar excess of dye). The dye-functionalised 
antibodies were purified by using a Zeba Spin desalting column with a 40 kDa 
MWCO (Thermo Fisher, IL, USA) to remove unreacted dye. The coupling efficiency 
was determined by performing absorbance spectroscopy on the dye-labelled antibody 




4.2.3.2 Conjugation of peptides to QDs 
Peptide sequences were synthesised with QD-binding motifs. His-tagged peptides are 
designed to self-assemble onto the ZnS surface of QDs via metal-affinity 
coordination. Biotinylated peptides are designed to bind to SA-coated QDs via a non-
covalent but high-affinity biological interaction between biotin and SA. QDs and 
peptides were transferred into 25 mM HEPES buffer (pH 7.5), 10 mM MgCl2, 0.01% 
w/v BSA (HEPES/Mg/BSA buffer), at RT. Buffer exchange into HEPES/Mg/BSA 
buffer was carried out via centrifugal filtration, as described in Section 2.2.2. The SA-
conjugated QDs were simply diluted into HEPES/Mg/BSA buffer. In order to 
conjugate peptides and QDs, solutions of each were mixed in the desired molar ratio 
and incubated at RT for 60 mins. 
 
4.2.3.3 Conjugation of peptides to Au NPs 
uPA substrate peptides (in 5 mM TCEP solution) and Nanogold (in 10% v/v 
isopropanol) were mixed at a molar ratio of 10:1 in 25 mM HEPES (pH 7.5) and kept 
at 4 °C for 24 h. Unlabelled peptide was removed by spin dialysis using a 10 kDa 
MWCO centrifugal filtration unit (Millipore, Massachusetts, USA) at 5,000g for 12 
minutes, repeated twice, with the inclusion of 0.01% w/v BSA and 10 mM MgCl2 at 
the second step. The concentration of gold was calculated by UV/Visible 
spectroscopy using the extinction coefficients listed in Table 6 and the conjugate was 
stored at 4 °C until use.  
 
4.2.4 UV/Visible absorbance spectroscopy and fluorimetry 
UV/Visible absorbance spectroscopy was carried out using a NanoDrop 2000c with 
cuvette capability (Thermo Scientific, Delaware, USA) and quartz cuvettes (Hellma 
Analytics, Müllheim, Germany). The extinction coefficients in Table 6 were used to 
determine the concentrations of the NPs and biomolecules used in this chapter. 
Fluorescence spectra were recorded in the spectrophotometer mode using a 
SpectraMax M5 microplate reader with an excitation wavelength 405 nm and cutoff 





Molecule ε(280 nm) /  
M-1cm-1 
ε(663 nm) /  
M-1cm-1 
ε(420 nm) /  
M-1cm-1 
ε(548 nm) /  
M-1cm-1 
ε(638 nm) /  
M-1cm-1 
AF660 dye     11,000 110,000 n. a. n. a. n. a. 
IgG antibody 203,000 negligible n. a. n. a. n. a. 
Monomaleimido 
Nanogold*  
n. a. n. a. 110,000 n. a. n. a. 
QD565 n. a. n. a. n. a. 300,000 n. a. 
QD655 n. a. n. a. n. a. n. a. 800,000 
Table 6: Molar extinction coefficients for molecular species used in this chapter. Data 
supplied by Life Technologies, except for *(Data supplied by Nanoprobes) 
 
4.2.5 Experimental design 
4.2.5.1 Single enzyme assays 
HER2 substrate peptide was incubated with HER2 kinase (17 µM peptide and 0.64 
mM ATP) in HEPES/Mg/BSA buffer at 38.5 °C, for 3 h. The peptides were 
conjugated to QD655s at specific peptide-QD ratios after the enzyme incubation. 
Peptide-functionalised QDs were treated with AF660-labelled anti-phosphotyrosine at 
specific antibody-QD ratios, for 1 h at RT (in darkness), to form a FRET coupling 
between the QDs and the AF dye molecules. 10 µL aliquots of the QD-peptide 
mixture were loaded onto a black 384-well plate (Corning, MA, USA). Fluorescence 
spectra in the region 600 nm – 750 nm (excitation wavelength 405 nm, cutoff 435 nm) 
were recorded as described in Section 1.2.1.1. 
The Au NP-labelled uPA substrate peptide was incubated with uPA protease (3.7 µM 
peptide) in HEPES/Mg/BSA buffer at 38.5 °C, for 3 h. The peptides were conjugated 
to QD565s, QD525-SAs or QD525-PEG-SAs at specific peptide-QD ratios after the 
enzyme incubation. 10 µL aliquots of the QD-peptide mixture were loaded on a black 
384-well plate (Corning, Massachusetts, USA). Fluorescence spectra in the region 490 
nm – 560 nm (excitation wavelength 405 nm, cutoff 435 nm) were recorded as 
described in Section 1.2.1.1. 
 
4.2.5.2 Multiplexed enzyme assays 
The multiplexed enzyme assays were carried out via one of two different methods. 
The first method was as follows: Two mixtures, A and B, were prepared. To prepare 
mixture A, Au NP-labelled His-tagged uPA substrate peptide and unlabelled His-
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tagged uPA substrate peptide were incubated with QD565s (0.5 µM Au NP-labelled 
uPA substrate peptide, 3 µM unlabelled peptide; 50:1 total peptide:QD ratio) in a total 
volume of 26 µL, prepared in HEPES/Mg/BSA buffer, for 1 h at RT. To prepare 
mixture B, His-tagged HER2 substrate peptide was incubated with HER2 kinase, uPA 
protease, and ATP (17 µM peptide and 0.64 mM ATP) in a total volume of 8.6 µL in 
HEPES/BSA/Mg buffer for 15 mins. The solutions A and B were mixed well, and 
incubated at 38.5 °C, for 3 h. Finally, the enzyme-peptide mixture was added to a 
mixture of QD655 and AF660-labelled anti-phosphotyrosine antibody (12:1 Ab:QD 
ratio) and incubated for 1 h at RT, protected from light. Fluorescence spectra in the 
region 480 nm – 750 nm (excitation wavelength 405 nm, cutoff 435 nm) were 
recorded as described in Section 1.2.1.1. 
The second method was as follows: The HER2 peptide substrate (17 µM) and Au NP-
labelled biotinylated uPA peptide substrate (3.7 µM) were incubated with HER2 
kinase, uPA protease and ATP (0.64 mM), in a total volume of 11 µL prepared in 
HEPES/Mg/BSA buffer, at 38.5 °C, for 3 h. An aliquot of 7.8 µL of the peptide-
enzyme mixture was added to a solution of QD525-SA (2.85 µL of 100 nM stock) and 
QD655 (13.32 µL of 100 nM stock) in the same buffer for 1 h at RT, giving a uPA 
substrate peptide-QD525 ratio of 100:1 and a HER2 substrate peptide-QD655 ratio of 
100:1. Finally, AF660-labelled anti-phosphotyrosine was added, and incubated for 1 h 
at RT, protected from light. Fluorescence spectra in the region 480 nm – 750 nm 
(excitation wavelength 405 nm, cutoff 435 nm) were recorded as described in Section 
1.2.1.1. 
 
4.3 Results and discussion 
Before developing a multiplexed assay for HER2 and uPA activity, first systems for 
detection of HER2 alone and uPA alone were optimised. The LOD of each individual 
assay was determined, before considering strategies for simultaneous detection. 
Finally, the significance of the results is discussed in the context of enzyme sensing 




4.3.1 Peptide synthesis 
HER2 substrate peptide and uPA substrate peptide were analysed by MALDI mass 
spectrometry. Figure 49a shows the mass spectrum for HER2 substrate peptide, with a 
peak indicating the expected MW of 1942 Da. Figure 49b shows the mass spectrum for 
uPA substrate peptide, with a peak indicating the expected MW of 1871 Da. 
 
Figure 49. MALDI mass spectra of synthetic substrate peptides. A. Chemical structure 
of HER2 substrate peptide. a. MALDI mass spectrum for HER2 substrate peptide, 
with the main ionisation peak (A+H+) indicating a peptide molecular weight of 1942 
Da. B. Chemical structure of His-tagged uPA substrate peptide. b. MALDI mass 
spectrum for His-tagged uPA substrate peptide, with the main ionisation peak (B+H+) 
indicating a peptide molecular weight of 1871 Da. The matrix used was alpha-cyano 
4-hydroxy cinnamic acid.  
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4.3.2 Dye-antibody conjugation 
The yield of the dye-antibody coupling reaction was quantified via absorbance 
spectroscopy. After purification of the dye-labelled antibody, the respective 
concentrations of AF660 and anti-phosphotyrosine IgG were determined. It was 
assumed that all unreacted dye had been removed due to the purification process. 
Molar extinction coefficients at relevant wavelengths are given in Table 2.  
Representative data for a single labelling is shown in Table 7. Note that the peak 
signal at 280 nm (IgG absorbance) must be corrected for off-peak dye absorbance. 
From this data, the dye-antibody ratio was calculated as 5.8, which represents a 58 % 











280 0.970 0.740 3.6 
AF660 dye 663  2.30 2.30 21 
Table 7: Absorbance of dye-antibody conjugates, measured by UV/Vis spectrometry. 
Concentrations were determined using the molar extinction coefficients listed in Table 
6. *The corrected absorbance was calculated as detailed in Section 2.2.4.1. 
 
4.3.3 Detection of HER2 by QD-based assay 
The HER2 kinase detection system was based on the generic transferase assay 
described in Section 2. A number of optimisations were carried out in order to ensure 
a suitable activity-based response. 
The effect of changing the concentration ratio of peptides:QDs was investigated by 
titrating a positive control peptide containing a phosphorylated tyrosine (pY-HER2 
peptide; for sequences see Section 4.2.2.2) against a constant concentration of 
QD655s. Figure 50 shows the system response after incubation with AF660-labelled 
anti-phosphotyrosine antibody. An increase in peptide number has a positive effect on 
FRET signal by increasing the probability of antibody assembly. By presenting a 
greater number of antibody binding sites, there is a resultant increase in the number of 
degrees of freedom, favouring assembly of multiple antibodies. The highest signal 
was observed at a peptide-QD ratio of 100:1, and at a concentration of 200 peptides 
per QD, a decrease in the PL peak ratio is indicative of a possible saturation of the QD 
surface by excess peptide. In situations where excess peptides are present in solution, 




Figure 50. Ratio of PL intensities at 695 nm and 645 nm plotted against molar ratio of 
HER2 positive control (pY-HER2) peptide assembled on QD655s prior to 
development with AF660-labelled anti-phosphotyrosine. Differently-coloured data 
points represent independent experiments. (Antibody-QD ratio of 15:1). 
hence precluding their binding at the QD surface. The positive control peptide 
titration suggested that a peptide:QD ratio of 100:1 would provide the best response 
level for the HER2 assay. 
Owing to concerns about QD stability (see Section 2.3.4), it was decided to test the 
enzyme assay response at peptide:QD ratios above and below 100:1. HER2 samples 
were assayed using the method set out in Section 4.2.5.1, changing the peptide 
concentrations so that the final ratio of peptide:QD would be either 60:1 or 180:1. 
Figure 51A and B (red spectra) show the spectral response after incubation of QD-
peptides with AF660-labelled anti-phosphotyrosine. In panels C and D, controls 
omitting ATP (blue spectra) or both ATP and HER2 (black spectra) are shown. It 
should be noted that altering the peptide:QD ratio caused negligible variation in the 
observed spectra, for either control. However, the introduction of HER2 in the 
absence of ATP (i.e. an inactive enzyme) caused a drop in QD PL. Comparing the 
controls with the active HER2 samples - for the active enzyme, there is a considerable 
drop in QD655 PL, accompanied by the onset of an emission peak at 695 nm, 
characteristic of AF660 emission. This spectral change is attributed to FRET, arising 




Figure 51. PL emission spectra for enzyme modified peptides and controls conjugated 
to QD655s and incubated with AF660-labelled anti-phosphotyrosine. Red spectra - 
HER2 substrate peptides incubated with 172 nM HER2 and 0.64 mM ATP; blue 
spectra – ATP omitted; black spectra – ATP and HER2 omitted.  A – peptides 
conjugated at 60:1 peptide:QD ratio. B – 180:1 peptide:QD ratio. C and D have been 
expanded to show the full range, highlighting the spectral regions corresponding to A 
and B. (AF660-labelled anti-phosphtyrosine added at an antibody-QD ratio of 10.4:1). 
HER2 activity). The change in response due to the presence of ATP indicates that the 
assay is sensitive to the activity of HER2, and does not respond in the same way to the 
presence of enzyme alone, although there was some evidence of a non-specific 
interaction that depressed the PL of the QDs upon addition of the HER2 (comparing 
the blue and black spectra, of the two controls). For the HER2 samples, at the higher 
peptide:QD ratio the signal I695 nm/I645 nm was twice as high. This can be understood by 
considering that there would be a larger number of accessible antibody binding sites 
available at 180 peptides per QD than at 60 (assuming a constant proportion of 
peptides phosphorylated). Hence the expected FRET signal would be higher. 
Following from the positive control and enzyme tests, it was decided to use a QD-
peptide ratio of 100:1 for further optimisation of this system. 
HER2 at concentrations of 19 nM and 57 nM (used as received – see Section 4.2.1) 
and controls omitting enzyme or ATP were assayed using the optimised detection 
system, with the FRET response and spectral peak components shown in Figure 52. 




Figure 52. HER2 titration (enzyme as received). Enzyme incubated with HER2 
substrate peptide prior to conjugation to QD655s and development of signal via 
addition of AF660-labelled anti-phosphotyrosine. Squares - 0.64 mM ATP present in 
enzyme reaction mixture; triangles - ATP omitted. A - Ratio of peak intensities at 695 
nm and 645 nm plotted against concentration of HER2. B - Peak PL intensity at 695 
nm (AF660 response) and at 645 nm (QD655 response) plotted against concentration 
of HER2. (Peptide-QD ratio of 100:1; AF660-labelled anti-phosphotyrosine added at 
an antibody-QD ratio of 31:1). 
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negative controls omitting ATP are shown using triangular data points. Figure 52A 
shows the trend for I695 nm/I645 nm to increase when ATP was present, whereas the 
control signal had a tendency towards remaining constant, within the range of 0.04-
0.05. These observations would suggest that the assay was responsive to only the 
active form of HER2. However, upon analysis of the spectral components in Figure 
52B, the trend for I645 nm to decrease in line with increasing HER2 concentration was 
observed. This indicates that there was a non-specific interaction affecting the QD PL 
due to the addition of increasing amounts of HER2. It was not clear at this juncture 
whether the non-specific interaction involved the enzyme or one of the storage buffer 
components, and hence it was decided to investigate the effect of individual buffer 
components on QD emission.  
A list of HER2 storage buffer components and concentrations is given in Section 
4.2.1. Addition of most of these components at relevant concentrations did not have 
an effect on PL of the QDs; however the response in the presence of DTT was to 
significantly decrease the emission of the QDs (see Figure 53). In the concentration 
range of 1 µM to 10 µM (a typical concentration range that the QDs would be 
exposed to), there was a drop of 29% in peak PL. This can be compared with the 
response upon increasing the HER2 concentration in the absence of ATP from 19 nM 
to 57 nM (Figure 52B - blue triangular data points). In this case, there was a drop of 
17% in peak PL. The results of the DTT titration suggest that this decrease in PL can 
be attributed to the addition of DTT to the QDs. Even though DTT has been used  as a 
capping agent to prepare water-soluble QDs [144], the molecular binding interaction 
is based on a dithiol linkage, as opposed to a single thiol in the case of MPA. Hence, it 
might be expected that the DTT would displace MPA from the QD surface. Jeong et 
al. [145] investigated the effect of thiol binding on CdSe/ZnS QDs, and found that the 
chemical nature of the thiol-surface interaction can affect the QY. In addition, 
displacement of the MPA, as well as imperfect surface coverage causing exposure of 
surface defects [14] may be responsible for the decrease in PL observed at high DTT 
concentrations. 
After observing the effect of DTT on the PL of the QD655s, it was decided to attempt 
to remove the storage buffer components from the HER2 enzyme solution, using a 
desalting column (Zeba filter, Fisher Scientific, Loughborough, UK) to perform buffer 
exchange into 25 mM HEPES, as per the manufacturer’s instructions. Figure 54 




Figure 53. QD655s in the presence of dithiothreitol (DTT). Peak PL at 655 nm is 
plotted against final concentration of DTT present in each sample. The error bars 
represent the standard deviation of 5 samples.  
 
Figure 54. UV absorbance spectrum of HER2 kinase as received (solid line) and 





Figure 55. HER2 titration (enzyme desalted against 25 mM HEPES buffer). Enzyme 
incubated with HER2 substrate peptide prior to conjugation to QD655s, and signal 
developed via addition of AF660-labelled anti-phosphotyrosine. Squares - 0.64 mM 
ATP present in enzyme reaction mixture; triangles - ATP omitted. A - Ratio of peak 
intensities at 695 nm and 645 nm plotted against concentration of HER2. B - Peak PL 
intensity at 695 nm (AF660 response) and at 645 nm (QD655 response) plotted 
against concentration of HER2. (Peptide-QD ratio of 100:1; AF660-labelled anti-
phosphotyrosine added at an antibody-QD ratio of 16:1). 
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(solid line) and after the desalting procedure (dashed line). The absorbance at 280 nm 
was used to measure total protein concentration, referenced to an initial HER2 
concentration of 100 µg/mL. 
A serial dilution of HER2 (starting concentration of 60 nM, 2-fold dilutions, 3 
independent measurements), was assayed, with the FRET response and spectral peak 
components shown in Figure 55. HER2 samples containing the cofactor, ATP, are 
indicated by square data points; the negative controls omitting ATP are shown using 
triangular data points. Figure 55A shows the trend for I695 nm/I645 nm to increase when 
ATP was present, whereas the control signal remained constant. The spectral peak 
components are shown in Figure 55B. In the case of the HER2 samples, a 
characteristic FRET response was observed, with a tendency for I695 nm to increase at 
higher HER2 concentrations accompanied with decreases in I645 nm. The negative 
control samples showed no concentration-dependent change in PL. In this case, the 
assay was responsive to only the active form of HER2, with no signal interference 
from buffer components. The LOD was determined by the concentration at which the 
FRET signal was greater than the control signal by 2σ (as described in Section 2.3.6). 
For HER2, the LOD of 7.5 nM is below the negative/positive cut-off set by Konecny 
et al. [30] (see Section 4.1).  
 
4.3.4 Detection of uPA by QD-based assay 
In addition to the detection of kinase activity, it was necessary to develop a system 
capable of sensing protease activity, to allow for multiplexed detection of HER2 and 
uPA activity. As discussed in Section 1.4.4, Au NPs have been found to quench the 
PL of QDs [21], and it was decided to exploit this interaction for the sensing of 
protease activity, utilising a similar methodology to that of Kim et al. [76]. Two 
formats were explored for this assay; both involved labelling uPA substrate peptides 
with Au NPs, incubating the peptides with uPA protease, and then coupling the 
enzyme reaction products to QDs. The two systems differed in the conjugation 
approach utilised; in the first instance, a His tag was used for directly coupling to the 
ZnS surface of QD565s; in the second case, QD525-PEG-SA and QD525-SA were 
used, and the peptide substrates were biotinylated, making use of the high-affinity 
biotin-SA interaction to couple the peptides to the QD surface. 




Figure 56. Peak PL intensity of QD565s at 555 nm plotted against molar ratio of Au 
NP-labelled His-tagged uPA substrate peptide : QDs. PLs are normalised against a 
control sample containing no peptide. 
 
through His tag-metal coordination was investigated. The concentration ratio of Au 
NP-labelled His-tagged uPA substrate peptide:QD565s was varied, and the effect on 
peak PL was monitored. In Figure 56, the peak PLs, normalised against a control 
containing no peptide, are plotted. A peptide:QD ratio of 100:1 was sufficient to 
quench the QD565 PL to 3% of the control value, and was used in the subsequent 
assay tests. To test the assay response, varying concentrations of uPA were incubated 
with the substrate peptide prior to immobilisation on the QDs. Figure 57 shows the 
change in peak QD565 PL between samples containing uPA and a control containing 
no enzyme. The assay was sensitive to uPA concentrations in the range 300-1000 
ng/mL. 
It was then decided to investigate the quenching of SA-coated QD525s by proximal 
binding of Au NP-peptides mediated by biotin-SA coupling. Two types of SA-coated 
QD525 were used; QD525-SA, where the SA is covalently coupled directly to the 
amphiphilic surface coating of the QD; and QD525-PEG-SA, where the SA is bound 
via a PEG linker. Figure 58 shows the emission spectra of both types of QDs after 
incubation with a 100:1 ratio of Au NP-labelled biotinylated uPA substrate peptides 




Figure 57. Quantification of uPA activity by monitoring PL of QD565s functionalized 
with Au NP-labelled His-tagged uPA substrate peptides. Change in PL from samples 
without enzyme is plotted after incubation with varying concentrations of uPA.  
(Peptide-QD ratio of 100:1). Fitted curve is a 4-parameter logistic plot. 
 
Figure 58. PL emission spectra of QD525 streptavidin conjugates decorated with a 
ratio of 100:1 peptides per QD. Closed triangles - QD525-SA incubated with 
biotinylated peptides labelled with Au NPs. Closed circles - QD525-PEG-SA 
incubated with biotinylated peptides labelled with Au NPs.  Open triangles – 
biotinylated peptides without Au NP labels incubated with QD525-SA.  
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triangular data points. The resulting peak PL of the QD525-PEG-SAs (round data 
points) was 65% of the control value, whereas the peak PL of the QD525-SAs (closed 
triangular data points) was only 10% of the control. The Au NP-mediated quenching 
of QD PL is a distance-dependent process, and hence these data suggest that the Au 
NPs are closer to the QD surface when bound to the QD525-SAs. The QD525-SAs 
were used in further optimisation of the assay. To optimise the concentration ratio of 
Au NP- labelled biotinylated uPA substrate peptide:QD525s, the effect on peak PL 
was monitored at different ratios. Control samples containing Au NP-labelled His-
tagged uPA substrate peptides at equivalent peptide concentrations were included. In 
Figure 59, the peak PLs, normalised against a negative control containing no peptide, 
are plotted. For the biotinylated peptide samples (triangular data points), the specific 
biotin-SA interaction is responsible for the quenching of QD PL with increasing 
peptide concentration. The controls (square data points) indicate a large degree of 
quenching by non-specific binding interactions, which may be evidence of the His tag 
penetrating the QD525-SA passivation layer. This non-specific binding was a factor 
for consideration in the design of the multiplex assay discussed in Section 4.3.5. 
 
Figure 59. Peak PL intensity of QD525-SAs at 520 nm plotted against molar ratio of 
Au NP-labelled uPA substrate peptide : QDs. PLs are normalised against a control 
sample containing no peptide. Triangles – biotinylated uPA substrate peptide; squares 
– His-tagged uPA substrate peptide.  
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A series of experiments were carried out to determine the effect of free Au NPs on the 
PL of the QD525-SAs. The first test was to incubate QD525-SAs with free Au NPs at 
a molar ratio of 100:1. The second test was designed to determine the effect of 
saturating protease concentration, so that potentially all peptides would be cleaved. In 
this way, there would be no Au NPs proximally bound to the QDs. QD525-SAs were 
decorated with Au NP-labelled biotinylated uPA substrate peptides, incubated with 
uPA protease at a saturating concentration of 3000 ng/mL (determined from the uPA 
titration shown in Figure 57). The emission spectra were normalised against a control 
without Au NPs, and plotted in Figure 60. The presence of free Au NPs (closed 
triangular data points) caused the QD525-SA peak PL to decrease to 61% of the 
control, while the incubation with saturating uPA (square data points) resulted in a 
final peak PL corresponding to 59% of the control. Simply having Au NPs present in 
solution did not quench the QD525-SA PL to the same extent as by proximally 
binding the Au NPs via peptide coupling (Figure 58, closed triangular data points). 
This observation validates the use of peptide-coupled Au NPs in the protease assay, 
and also explains why the maximum recovered PL due to proteolytic cleavage has a 
limit, set by the quenching level of free Au NPs.    
 
Figure 60. PL emission spectra of QD525 streptavidin conjugates (open triangles); 
incubated with 100:1 Au NPs per QD (closed triangles); decorated with a ratio of 
100:1 Au NP-labelled biotinylated peptides per QD and incubated with 3000 ng/mL 




Figure 61. Quantification of uPA activity by monitoring PL of QD525-SAs 
functionalised with biotinylated uPA substrate peptides labelled with Au NPs (+Au) 
or unlabelled  peptides (-Au). Change in PL from samples without enzyme is plotted 
after incubation with varying concentrations of uPA. (Peptide-QD ratio of 100:1). 
 
Figure 62. Ratio of peak PL emissions of QD525-SAs bound to Au NP-labelled (+Au) 




A serial dilution of uPA (starting concentration of 800 ng/mL, 2-fold dilutions, 3 
independent measurements) was assayed using the QD525-SA-peptide-Au 
assemblies. Figure 61 (closed triangular data points) shows the difference in peak 
QD565 PL between samples containing uPA and a control containing no enzyme, 
plotted against uPA concentration. Negative controls with the same concentrations of 
uPA, but using peptides lacking Au NP labelling are indicated with open triangular 
data points. The change in PL of the uPA samples shows a trend to increase with 
increasing uPA concentration, whereas the controls show a negligible change in PL. 
The limited increase in PL in the case of peptides without Au NP labelling, and the 
fact that the contribution of free Au NPs to the overall quench of QDs has been 
accounted for, indicate that the uPA-dependent changes in QD525-SA PL were due to 
cleavage and release of the Au NPs, and not any non-specific interaction. Hence, the 
assay was sensitive to the proteolytic activity of uPA. The LOD was determined as 
described in Section 2.3.6. For uPA, a LOD of 50 ng/mL was measured, which is 
below the negative/positive cut-off set by Konecny et al. [30] (see Section 4.1). 
Further analysis of the uPA titration data is shown in Figure 62, where the ratio 
between signals for samples containing either Au NP-labelled peptides or unlabelled 
peptides, at each uPA concentration, is plotted. This data should be compared with the 
Au NP-biotinylated peptide:QD-SA ratio titration (triangular data points, Figure 59) 
which shows the quenching due to varying the number of Au NPs surrounding the 
QDs. At the LOD (50 ng/mL uPA), the ratio of the emissions corresponds to the same 
level as would be observed for an Au NP-peptide:QD ratio of 15:1.  Hence, at this 
concentration, it can be estimated that ~85% of peptides were cleaved. In the uPA 
titration, the normalised response seems to saturate at a ratio of about 0.6; this 
corresponds to the quenching level due to free gold in solution (see Figure 60) and 
represents an upper limit for the assay. 
 
4.3.5 Development of multiplex assay for simultaneous detection of 
HER2 and uPA 
Having optimised the assays for both HER2 kinase and uPA protease, the design of a 
system capable of detecting both enzymes with a simultaneous readout was attempted. 
For this system to be used in a diagnostic setting, it would be necessary for the 
multiplex assay to recognise a mixture of the two enzymes, rather than a sequential 
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addition of one enzyme after the other. Hence, a number of factors had to be 
considered in the construction of the assay, namely substrate-enzyme cross-reactivity; 
spectral overlap of the fluorescent reporters; and dilution of enzyme-specific signal 
due to interactions with competing assay components.  
The first question to be addressed was the likelihood of cross-reactivity between the 
HER2 kinase and the uPA substrate peptides, and the uPA protease and the HER2 
substrate peptides. Such interactions could affect the measured activity of the intended 
enzyme target, resulting in false negatives. Considering the enzyme recognition 





There are no common motifs within the respective sequences (i.e. no RS motif within 
the HER2 substrate peptide, and no tyrosines within the uPA substrate peptide); hence 
both enzymes should act on their own target substrate only, with no cross-reactions. 
Secondly, spectral overlap was considered when selecting the QD emission 
wavelengths; for the detection of HER2, QD655s were used, and for simultaneous 
detection of uPA, QD525-SAs or QD565s were used. These QD pairs offered 
sufficient spectral separation due to the small FWHM (<35 nm) of the QD emission 
spectra. 
Finally, in order to maximise the enzyme-specific signals in the multiplex format, 
strategies to ensure segregation of the enzymatic products were considered, so that 
each type of QD would immobilise only one type of enzyme substrate peptide. Both 
of the following were investigated: pre-functionalisation of each type of QD with 
specific peptides prior to enzyme incubation using an identical coupling approach; 
and specific functionalisation of the QDs after the enzyme incubation using 
orthogonal coupling approaches. 
A potential pre-functionalisation strategy would be to prepare separate populations of 
peptide-functionalised QDs, then add in the HER2/uPA enzyme mixture. However, in 
line with the results for p300 HAT (Section 2.3.5), it was not possible to achieve 
detection of HER2-mediated phosphorylation when the substrate peptides were 
immobilised on the QD surface. However, the work of Kim et al. [76] suggested that 




Figure 63. QD655 FRET response and QD565 PL in mixed samples of QDs exposed 
to control peptides or uPA protease (10,000 ng/mL). A. Ratio of PL intensities at 695 
nm and 645 nm. B. PL intensity at 555 nm.  HER2 negative control – HER2 substrate 
peptide (630 nM); HER2 positive control – pY-HER2 peptide (630 nM); uPA 
negative control – no enzyme (uPA substrate peptide concentration – 175 nM). Final 
QD concentrations of 21 nM QD655 and 25 nM QD565; AF660-labelled anti-
phosphotyrosine added at a final concentration of 730 nM. 
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detection strategy, the following temporal sequence was followed: a) functionalisation 
of QD565 with Au NP-labelled His-tagged uPA substrate peptides; b) introduction of 
uPA, HER2, ATP, and HER2 substrate peptide; c) introduction of QD655 and AF660-
labelled anti-phosphotyrosine antibody.  
The interactions between assay components were probed by preparing a series of 
controls. As negative controls for HER2 detection, either the peptide or the enzyme 
was removed. As a positive control for HER2 detection, the HER2 substrate peptide 
was replaced by pY-HER2 peptide. As a negative control for uPA detection, the 
enzyme was removed. A control with no uPA peptide was included as a positive 
control for uPA detection. Samples containing uPA were also prepared. The effect of 
HER2 was not tested in this experiment. The assay responses are plotted in Figure 63. 
Panel A shows I695 nm/I645 nm with the responses grouped by identity of HER2 control, 
and panel B shows I555 nm grouped by identity of uPA control / uPA sample. 
Comparing the HER2 controls in Figure 63A, the FRET signals were lower in the 
absence of peptide than in the presence of HER2 substrate peptide, and the presence 
of pY-HER2 peptide resulted in the highest FRET signals. In terms of the uPA 
controls and sample shown in Figure 63B, considering first the tests in the absence of 
interfering HER2 peptides (blue bars), there was a clear increase in the PL between 
the uPA negative and positive controls, with the uPA protease response lying between 
these two extremes. The same trend was observed in the presence of HER2 substrate 
peptide (red bars). However, the presence of pY-HER2 peptide caused a large drop in 
the QD565 PL in all cases (green bars).  
The assay was responsive to the presence of uPA, even though the uPA substrate 
peptides were pre-immobilised on the QD565s. However, this was not the case when 
HER2 positive control peptide, pY-HER2, was present. Recalling the sequence of 
reagent addition, a low ratio (7:1) of Au NP-labelled peptides was used to 
functionalise the QD565s; this was done to avoid the presence of free Au NP-labelled 
peptides in solution. QD565s were exposed to 25:1 HER2 peptides per QD prior to 
the addition of QD655s. The FRET response upon exposure of QD655s to pY-HER2 
peptides was equivalent to the response observed upon exposure to ~3 peptides per 
QD, by comparison with the peptide ratio titration shown in Figure 50. Taking this 
into account, as well as the observed PL response of the QD565s in the presence of 
pY-HER2 peptide (green bars, Figure 63B), suggests that the peptide was responsible 




Figure 64. QD655 FRET response and QD565 PL in mixed samples of QDs exposed 
to control peptides, HER2 kinase (55 nM), or uPA protease (20, 000 ng/mL). A. Ratio 
of PL intensities at 695 nm and 645 nm. B. PL intensity at 555 nm. HER2 negative 
control – HER2 substrate peptide (1.5 µM), HER2, no ATP; HER2 positive control – 
pY-HER2 peptide (1.5 µM); uPA negative control – no enzyme; uPA positive control 
– His-tagged uPA substrate peptide, no Au NP label. Final QD concentrations of 25 
nM QD655 and 30 nM QD565; AF660-labelled anti-phosphotyrosine added at a final 
concentration of 255 nM. 
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followed by antibody-dye binding quenching that QD565 PL by energy transfer. Due 
to the addition sequence of reagents, and to try to avoid binding of HER2 peptides on 
the QD565s, it was decided to protect the QD565 surface by including peptides 
without Au NP labels in the QD565 functionalisation step. 
A second set of controls and enzyme samples were then tested. As a negative control 
for HER2 detection, HER2 enzyme was present, but ATP was removed. As a positive 
control for HER2 detection, the enzyme was removed and the HER2 substrate peptide 
was replaced by pY-HER2 peptide. For the functionalisation of QD565s, His-tagged 
uPA substrate peptides with no Au NP labels were included at a peptide:QD ratio of 
43:1 along with the 7:1 ratio of Au NP-labelled His-tagged uPA substrate peptides. As 
a negative control for uPA detection, the enzyme was removed; as a positive control, 
the 7:1 Au NP-labelled His-tagged uPA substrate peptides were replaced with 
unlabelled peptides. The assay responses are plotted in Figure 64. Panel A shows I695 
nm/I645 nm with the responses grouped by identity of HER2 control / HER2 sample, and 
panel B shows I550 nm grouped by identity of uPA control / uPA sample. Comparing 
the HER2 controls and sample in Figure 64A, the presence of pY-HER2 peptide 
resulted in the highest FRET signals, but there was no elevation in FRET signals 
apparent due to the presence of HER2 in the enzyme sample. In terms of the uPA 
controls and sample shown in Figure 64B, the trends observed in Figure 63B were no 
longer apparent and there was no Au NP-dependent quenching of PL observed. 
However, the presence of pY-HER2 peptide caused a large quench in the QD565 PL 
in all cases (green bars). The emergence of a large FRET response for the HER2 
positive control suggests that pY-HER2 peptides were binding to the QD655s. By 
comparison with the peptide ratio titration (Figure 50), this was equivalent to a 
concentration ratio of ~10 peptides per QD. However, the quench in QD565 PL in the 
presence of pY-HER2 peptides (green bars, Figure 64B) suggests that these peptides 
were still binding to the QD565s. The lack of Au NP-dependent quench of the QD565 
PL may be attributed to different binding affinities for Au NP-labelled and non-
labelled peptides towards the QD565 surface, resulting in negligible binding of 
proximal Au NPs. The passivation of the QD565 surface by unlabelled uPA substrate 
peptides did not improve the response of the multiplex system, and it was decided to 
pursue an alternative strategy for segregation of the different enzymatic products.  
In order to improve the multiplexed assay response, the following orthogonal 




Figure 65. PL emission spectra of mixtures containing bioconjugated QD525-SA 
(final concentration of 10 nM) and QD655 (final concentration of 50 nM). QD525-SA 
decorated with Au NP-labelled (A) or unlabelled (B) biotinylated uPA substrate 
peptides (final peptide concentration of 1000 nM). QD655 decorated with HER2 
substrate peptides (C) or pY-HER2 peptides (D) (final peptide concentration of 5000 
nM) and incubated with AF660 dye-labelled anti-phosphotyrosine (final antibody 
concentration of 785 nM). 
of QD525-SAs and biotinylated uPA substrate peptides and a second coupling pair of 
QD655s and His-tagged HER2 substrate peptides. The following temporal sequence 
was followed: a) incubation of uPA, HER2, and ATP with HER2 substrate peptide 
and uPA substrate peptide; b) introduction of QD525-SAs and QD655s; c) 
introduction of AF660-labelled anti-phosphotyrosine antibody. The interactions 
between assay components were probed by preparing a series of controls. As a 
negative control for HER2 detection, the enzyme was removed. As a positive control 
for HER2 detection, the HER2 substrate peptide was replaced by pY-HER2 peptide. 
As a negative control for uPA detection, the enzyme was removed. As a positive 
control for uPA detection, the Au NP-labelled biotinylated uPA substrate peptide was 
replaced by peptide with no Au NP labels. The spectral response to each of the control 
combinations is shown in Figure 65. Considering first the HER2 positive controls, the 
presence of pY-HER2 caused a large FRET response in terms of quenching of the 
QD655 emission at 645 nm, and onset of dye emission at 695 nm. For the uPA 




Figure 66. Simultaneous detection of HER2 and uPA using multiplex assay. A. Ratio 
of PL intensities at 695 nm and 645 nm plotted against HER2 concentration in 
sample. (Range of uPA concentrations denoted by differently-shaped data points - 0 
ATP condition is shown for 80 nM HER2 only.) B. Change in PL at 520 nm plotted 
against uPA concentration (HER2 concentrations denoted by differently-shaped data 
points). Final reagent concentrations: Q655 (50 nM); Q565-SA (10 nM); HER2 
substrate peptides (5 mM); uPA substrate peptides (1 mM); AF660-labelled anti-
phosphotyrosine (785 nM). 
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quench in the QD525-SA emission at 520 nm. The spectral response of each QD was 
independent of the response of the other QD type. Here, despite a mixture of peptides 
present upon the introduction of QD525-SAs and QD655s, the orthogonality of the 
peptide-QD coupling allows the spectral responses to evolve independently. In terms 
of the multiplex assay, resolution of the activity of one enzyme type should not 
perturb the response due to the other enzyme type. 
The orthogonally-coupled multiplex assay was used to assay mixtures of HER2 and 
uPA at different concentrations. A negative control for HER2 activity, omitting ATP, 
was also included. The FRET response of the QD655s versus concentration of HER2 
is plotted in Figure 66A. The change in PL of the QD525-SAs with respect to samples 
containing no enzymes, plotted against concentration of uPA, is shown in Figure 66B. 
For each concentration of HER2, there are three data points representing the different 
concentrations of uPA added to the enzyme mixture and vice versa for the uPA plot. 
Hence, for each data point on panel A, there is a corresponding data point on panel B, 
taken from the same spectrum. Considering first the HER2 response, the trend was for 
I695 nm / I645 nm to increase when the concentration of HER2 increased. The negative 
control (open triangular data point) remained at the same level as samples with no 
HER2, indicating that the assay was still sensitive to HER2 activity. As can be seen 
by the clustering of the data points at each HER2 concentration, the concentration of 
uPA did not significantly affect the kinase detection signal. Considering the uPA 
response, the trend was for ∆I520 nm to increase when the concentration of uPA 
increased. As can be seen by the clustering of the data points at each uPA 
concentration, the concentration of HER2 did not significantly affect the protease 
detection signal. The groups of data at each enzyme concentration were 
distinguishable at the 95% confidence level. This test shows that the multiplex assay 
was able to discern the activities of different enzymes simultaneously, with each 
sample producing a unique combination of HER2 and uPA signals.  
 
4.3.6  Discussion 
A system for simultaneous detection of kinases and proteases was developed by 
incorporating QD-based sensing platforms from two different assays. The kinase 
sensing platform was based on the system described in Section 2 of this thesis, and in 
the publication by Ghadiali et al. [74], while the protease detection platform that was 
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incorporated drew inspiration from the work of Kim et al. [76]. In this discussion, the 
results of each step of the development of the multiplex assay are analysed in light of 
the existing literature, and the general applicability of the technique is considered. 
The HER2 detection assay described in Section 4.3.3 had a LOD of 7.5 nM HER2. 
Considering the specific activity of 1.1 nmol/min/mL enzyme and the LOD of 7.5 
nM, and the specific activities of the enzymes used in the kinase detection paper of 
Ghadiali et al. [72] (Abl kinase activity = 100 nmol/min/mL enzyme, LOD = 0.33 
nM), the detection sensitivity in terms of enzyme activity is consistent with previous 
assays. As a predictive tool, the LOD of 7.5 nM (corresponding to 200 fmol/mg in the 
work of Konecny et al. [30]) is sufficient when quantified in tandem with uPA or 
independently (the tolerance is 260 fmol/mg sensitivity if HER2 alone is to be used as 
a prognostic indicator [146]). In a preliminary experiment to investigate the 
applicability of the HER2 assay in a biologically-relevant setting (see Figure 67), 
HER2 samples were prepared in the presence of serum components (1% w/v HSA; 
the reference range of HSA in human serum is 3-5% w/v). It was possible to detect 
HER2 activity with these components present, suggesting that the assay could find 
application for clinical samples.  
 
Figure 67. PL emission spectra for QD605s in 1% w/v human serum albumin, 
functionalised with HER2 substrate peptides (circles); after incubation with 60 nM 
HER2 in the absence (triangles) or presence (squares) of 0.64 mM ATP. (Peptide-QD 




Finally, it is worth mentioning that HER2 is routinely screened in tissue sections of 
biopsy samples, particularly by antibody-based IHC. QDs have been used for this 
application [137], enabling physicians to quantitatively assign the progression of the 
disease on a standardised scale. However, the activity-based detection of HER2 by 
QDs represents a departure from the fluorescent labelling and imaging approach, and 
may potentially provide complementary information, without the need for 
complicated sectioning and immobilisation of tissue biopsy samples. 
The protease assay developed for the detection of uPA (see Section 4.3.4) had a LOD 
of 50 ng/mL uPA. This can be compared with the work carried out by Xia et al. [33], 
where bioluminescent donor proteins were coupled to QDs (acting as energy 
acceptors) via a uPA-specific peptide sequence. In this system, the LOD achieved was 
500 ng/mL. An explanation for the lower LOD found in the Au NP-QD system may 
be that Au NPs are more efficient quenchers of QD emission than QDs are of 
fluorescent proteins. The detection range of proteases is larger as a result, with a 
lower LOD. Kim et al. [76] reported a protease detection assay based on QD-SA 
conjugates quenched by proximal Au NPs. In solution, the maximum recovery of PL 
observed was 47%, but this was using pre-immobilised peptides, and the lack of full 
recovery could have been due to steric hindrance of the enzymes. In their surface-
based assays, the assay was shown to have a sensitivity for MMPs within the 
biological expression range. Interestingly, the maximum quenching level of 83% 
reported in that paper was lower than that found here (>90%). This may be due to the 
fact that in solution, it is possible to couple ligands to the QD-SAs in all directions, 
without restrictions due to having the QDs immobilised on a surface. The observed 
LOD of 50 ng/mL is lower than the clinically relevant LOD of 200 ng/mL (equivalent 
to 5.5 ng/mg as required by Konecny et al. [30] for prognosis determination when 
HER2 is also quantified) and is also sufficient when using uPA as a lone marker (in 
which case, a sensitivity of 135 ng/mL is required [147]). The system LOD may be 
improved further by using a smaller peptide:QD ratio. At very high peptide:QD ratios 
(see Figure 59), a small number of cleavage events would not cause a large change in 
PL compared to the case with small peptide:QD ratios (the gradient of the PL change 
per peptide is higher at low ratios). The drawback would be that the system would 
reach saturation at a lower protease concentration. These considerations were taken 
into account by Medintz et al. in the design of their proteolysis assay [70]. 
Fluorescence polarisation has also been used to detect protease activity; Jolley [52] 
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labelled trypsin substrate peptides with BODIPY (red) fluorescent dyes, and 
monitored the changes in fluorescence polarisation upon introduction of the protease, 
with a detection limit of 10 ng/mL trypsin. Although this method is highly sensitive, 
the choice of substrate is limited somewhat by molecular size requirements; the 
original substrate peptide and the subsequent cleavage fragments must exhibit 
significantly different fluorescence polarisation.  
In terms of multiplexing, uPA improves as a prognostic indicator when evaluated in 
combination with HER2 or when co-assayed with its inhibitor, plasminogen activator 
inhibitor 1 (PAI-1) [30, 127]. In the QD-based assay format, it would be possible to 
elucidate PAI-1 inhibitory action by including a system for simultaneously measuring 
uPA concentration as well as activity. This could be achieved by including QDs 
labelled with monoclonal antibodies raised against uPA and probed with secondary, 
dye-labelled polyclonal antibodies, potentially in a FRET relay format (as a way to 
extend the distance range of the FRET assay, see Section 2.3.7). If this were properly 
optimised in a homogeneous system, the sandwich assay would act as an internal 
control, and the protease activity-dependent assay would report on the effect of PAI-1 
on uPA activity. A sandwich-based concentration-dependent assay was realised in 
multiplex format by Goldman et al. [67].  
Modifying the HER2 and uPA assays for multiple-analyte detection required a 
consideration of interactions between diverse assay components. Specifically, 
parameters of importance included: off-target enzyme activity (i.e. HER2 acting on 
uPA substrate and vice versa); non-specific binding of substrate peptides to QDs (i.e. 
biotinylated uPA substrate peptide binding to QD655 or His-tagged HER2 substrate 
peptide binding directly to QD525-SA); and destabilisation of QDs by enzyme storage 
buffer components. Observation of the independence of HER2 activity signal on uPA 
concentration and vice versa (Figure 66) indicates that the effect of off-target enzyme 
activity was negligible. However, the depression of HER2 signal compared with the 
non-multiplex assay case (Figure 55A) indicates that some of the His-tagged peptides 
may be non-specifically binding on the QD525-SAs, as observed in Figure 59. 
Finally, it was observed that the DTT present in the HER2 kinase storage buffer 
quenched the PL of the QDs. This was alleviated by desalting the HER2 kinase 
against 25 mM HEPES buffer before use. 
In respect of the specific application of determination of breast cancer prognosis, the 
individual HER2 and uPA assays possessed low enough LODs for assignment of 
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negative/positive enzyme levels; however the HER2 signal was depressed in the 
multiplex format and so the multiplexing assay was not sensitive enough for the 
intended application. Nevertheless, the system can be considered as a demonstration 
of the detection concept, and the assay format could find utility in a range of different 
applications, such as biomarker screening for other diseases, and high-throughput 
drug discovery platforms (see Section 4.4). The assay design possesses a number of 
features that make it well-suited for multiplexing. In order to detect proteases, Au NPs 
were selected as quencher molecules because of their particularly strong efficiency 
and lack of re-emission [21], minimising the amount of spectral space required per 
analyte. For the detection of transferases, the use of dye-labelled antibodies affords 
the greatest flexibility in terms of selecting mutually exclusive overlapping QD-dye 
combinations for detection of separate analytes. Due to the non-specific interactions 
between His-tagged substrate peptides and MPA-capped QDs, even with QD 
passivation, it was shown that multiplex assays will require orthogonal coupling of 
enzyme substrates. This assay design lends itself to the incorporation of separate 
coupling chemistries, as there exists a wealth of chemistries available for orthogonally 
coupling peptides to surfaces [148]. An obvious bio-inspired extension would be to 
use complementary DNA sequences to ‘dial in’ binding specificity (coding for  
 
Figure 68. Multiplex assay concept, showing detail of a DNA-based coupling 
strategy. A His tag-ssDNA conjugate would be attached to the QD surface, while an 
enzyme-specific substrate would be conjugated via a complementary nucleotide 
sequence. The enzyme-modified residue is indicated in black. 
128 
 
specific analytes, similarly to the ‘bio barcode’ concept published by the Mirkin group 
[84, 85]). Figure 68 shows how such a coupling system might work in practice. Note 
that the use of ssDNA also imparts a directionality to the binding, allowing the 
antibody binding site (black) to be positioned close to the QD surface for maximum 
sensitivity. 
Multiplexing has been demonstrated in non-NP formats, but compared to the QD-
based assay are much more complicated and cumbersome to perform. Mass 
spectrometry is an emerging technique for phosphoproteomic analysis [149, 150], 
providing useful information about global phosphorylation within a sample, and could 
potentially help in understanding some of the kinase signalling pathways which are 
not accessible via standard antibody-based methods. The wide accessibility of mass 
spectrometry makes this a near-high throughput technique, albeit requiring some post-
processing and biochemical analysis. For this analysis to take place on a reasonable 
timeframe, the detection space is limited mainly to the transferase family of enzymes, 
particularly in the multiplex format. The kinase/protease multiplex described in this 
chapter could be used to provide complementary information to mass spectrometry; 
the kinase assay could provide information about phosphorylation of specific 
sequences, and the protease assay would reveal the presence of specific proteases. The 
sample could then be probed via mass spectrometry to reveal the identity of kinases 
present. For purified samples, it is possible to engineer substrates that can be acted on 
by specific hydrolase enzymes (the family of which proteases are a member) in a 
multiplex format, for example glycoside hydrolases [151], although the analysis of the 
mass spectrometry data would soon become cumbersome for more than two targets. 
Using mass spectrometry, it is possible to determine product-to-substrate 
concentration ratios. This parameter could be evaluated using the QD-based assays, 
using a calibration curve to determine percentages of modified substrates on the QD 
surface.  
Small molecule-based fluorescent assays have also been used in a multiplex format 
[152, 153]; these typically work by labelling a peptide substrate with a fluorescent 
molecule. The addition/removal of a functional group alters the fluorescence 
emission, allowing for activity-based detection to be achieved. In the work of Shults 
et al. [153], three kinase-dependent fluorescent substrates were prepared and tested in 
parallel on aliquots from the same sample of cell lysate (the reason the samples were 
tested in parallel, and not homogeneously, was because the same fluorescent dye was 
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used in all three cases.). Each substrate gave an enzyme-specific response, allowing 
for the relative activities to be determined. The drawback of this approach is that well-
to-well variation may affect the calculated ratios of enzyme activity. This method 
would not be able to provide a simultaneous readout from a single sample, precluding 
the introduction of an internal standard. In general, this method is not as generic or 
flexible as the QD-based multiplex assay, with the wide range of surface 
functionalities and/or emission wavelengths available. 
The eventual application of QD biomarker assays will be strongly dependent on 
whether the NP systems can be stabilised in biological media. Strategies that have 
been used to extend the applicability of NP-based assays into the biological domain 
include firstly, dilution [63]. This would be accessible in the case of the HER2 and 
uPA assays because of the demonstration that the LOD is lower than required for 
determination of negative/positive prognosis. Secondly, many ELISA-type assays 
using NPs include a washing step to reduce interference from biological components 
[66, 84, 85]. In the assays described in this chapter and in Chapter 2, the fact that the 
enzyme reaction is performed prior to the introduction of QDs means that a 
washing/buffer exchange step could be included to remove many of the interfering 
proteins present, to alter the pH and the ionic strength. These approaches, or a 
combination thereof, might therefore allow the MPA-coated QDs to be used in the 
assay without further modification. There is some evidence to suggest that His-tagged 
peptides can penetrate the PEG layer of PEG-passivated QDs [154], which could offer 
a strategy to improve the stability of QDs in biological media while still preserving 
the biosensing properties. 
In terms of the robustness of the orthogonal coupling interactions; the self-assembly 
interactions utilised possess some of the strongest affinity interactions that could be 
accessed via self-assembly. Both the SA-biotin and the His tag-QD interactions [155] 
are of similar or greater strength than most antibody-antigen interactions. An example 
of where the avidin-biotin interaction interfaced with QDs has been used in a 
biological setting can be found in the literature [156], where Jainswal et al. directly 
stained live cells that had been targeted with a biotin-expressing reporter molecule, 
using QDs functionalised with avidin molecules. In the case of the His tag-metal 
coordination; this chemistry is used extensively in His tag protein purification on 
Nickel-NTA columns, in complex biological samples such as whole cell lysate (the 
binding of His to Ni ions is directly relevant to the binding of His to Zn ions on the 
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QD surface [157]). In a recent paper published by Wang et al. [158], glutathione-
stabilised QDs were used to selectively capture poly-His tag peptides from a mixture 
of small molecules, peptides, and proteins in cell lysate. The multiplexing assay 
would certainly benefit from the use of ligands such as these to reduce non-specific 
binding when assaying real clinical samples. 
 
4.4 Conclusions and Outlook 
A QD-based system for the multiplexed determination of enzyme activity was 
demonstrated. The target analytes were enzymes from different families; HER2, a 
kinase, and uPA, a protease. Assays sensitive against HER2 alone and uPA alone 
were developed, with a LOD of 7.5 nM for HER2, and 50 ng/mL for uPA. These 
values correspond to the negative/positive prognostic levels set by Konecny et al. 
[30]. Negative controls indicated that the respective signals were activity-dependent. 
In order to engineer a system that was capable of simultaneously reporting on both 
HER2 and uPA when present in the same sample, it was necessary to consider 
strategies to ensure minimal interference from and perturbation of the signals 
generated by the activity of each enzyme. To address the problem of signal cross-talk, 
enzyme substrates were orthogonally functionalised and addressed to complementary 
QDs with different emission wavelengths. The QDs acted to sequester only one type 
of enzyme product, while also allowing for activity-dependent signals to be generated 
at distinct regions of the spectrum. 
It was possible to detect the two enzymes simultaneously, with the signal from each 
analyte independent of the concentration of the other. Hence, the assay concept was 
successfully demonstrated and afforded an insight into the engineering of multi-
component nanoscale assemblies. The multiplex assay suffered from a decrease in 
sensitivity with respect to the independent, single-target assays. Whereas the single-
target assays showed LODs suitable for the detection of the clinically relevant ranges 
(15 nM for HER2, and 200 ng/mL for uPA), this was not the case for the multiplexed 
assay. However, this does not preclude the use of the multiplexed assay in alternative 
biomarker-screening settings, or for other applications. This format used small sample 
volumes and would be amenable to automation in a high-throughput format. The 
ability to monitor activity of more than one enzyme simultaneously might find an 
application in drug development, particularly the discovery of potent drug 
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combinations that deactivate multiple pathways, or in the prediction of side-effects 
due to activation/deactivation of critical regulatory pathways or enzymes that might 
confer drug resistance. In the basic sciences, this system might present an attractive 


































This thesis has explored the development and application of a generic enzyme 
detection platform in a number of different scenarios, including acetyltransferase, 
kinase and protease detection, and in an integrated multiplex format. In this chapter, 
the main findings of the thesis will be presented, alongside suggestions for further 
research stemming from it. 
Using a generalisable assay design, it was proposed that activity-based detection 
systems could be designed based on the emission properties of semiconductor QDs. 
This hypothesis was tested by first designing a platform for the detection of HATs, 
then modifying the assay design for the detection of serine kinases. Finally, the 
modular nature of the QD-based assay was exploited to develop an assay for the 
multiplexed detection of a tyrosine kinase and a protease. 
In the Introduction, a number of existing enzyme assays were considered, establishing 
the need for tests with high analyte sensitivity but with minimal sample preparation. 
Optical detection using QDs addresses these issues, and as an added benefit QDs can 
be used in multiplexing assays. In Chapter 2, a novel target for NP-based assays, p300 
HAT was investigated. This enzyme has been implicated in the progression of breast 
cancer [96]. For this assay, a number of components similar to existing QD-based 
activity assays were utilised; namely, a bifunctional peptide sequence containing QD 
binding and p300 HAT recognition motifs, and a dye-labelled monoclonal antibody 
specific against acetyllysine. Incorporation of these new components into the enzyme 
detection assay allowed for the determination of enzyme activity with a LOD of 0.5 
nM p300 HAT, which compares well with the state of the art non-NP based assay 
(radioisotope labelling [48]). The assay was subsequently used to profile the potency 
of the p300 HAT inhibitor anacardic acid, indicating that the system was robust 
against the introduction of small-molecule drug candidates. Chapter 3 dealt with a 
number of issues arising from the detection of serine phosphorylation. In modifying 
the assay from Chapter 2, non-specific recognition of serine residues was observed, 
suggesting that alternative detection modalities would be required to achieve specific 
recognition of kinase-mediated phosphorylation. The alternative format involving 
biotinylation of the target residue and subsequent detection via binding of dye-
labelled SA was explored. Further strategies for resolving the detection issues were 
133 
 
discussed, with possible applications in situations where no specific antibody exists 
for the target of interest. 
In Chapter 4, a strategy for the multiplexed detection of HER2 tyrosine kinase and 
uPA protease activities was demonstrated. These two enzymes form a biomarker pair 
that has been suggested as a prognostic indicator for breast cancer [30], with the 
relative levels of each enzyme providing information about the metastasis-free 
survival of patients. In terms of the HER2 kinase assay, the system was based on the 
p300 HAT assay platform described in Chapter 2, but with a modification of the 
substrate peptide to include a HER2-specific recognition motif, and using anti-
phosphotyrosine antibodies to recognise the enzyme-mediated phosphorylation. The 
demonstrated LOD was 7.5 nM for HER2, which corresponds to the LOD required for 
providing meaningful prognostic information. For the detection of uPA protease, it 
was required to pursue an alternative QD-based sensing strategy, based on the 
physical cleavage of peptides linking the QD to emission-quenching Au NPs. This 
was based on the protease detection platform described by Kim et al. [76], with the 
protease cleavage motif altered to one that was specifically cleaved by uPA. The 
demonstrated LOD was 50 ng/mL for uPA, which again corresponds to the LOD 
required to provide meaningful prognostic information. Two different designs for 
achieving the multiplexed detection of HER2 and uPA were considered, with the 
more successful design being an orthogonal coupling strategy. By functionalising 
each enzyme substrate with a different binding motif (His tag or biotin), and coupling 
them to differentially-emitting QDs either capped with MPA or functionalised with 
SA, it was possible to probe mixed samples of HER2 and uPA and read out 
simultaneous signals with no significant cross-talk. The multiplex assay did not 
demonstrate the low LODs of the single-analyte assays; however this work showed 
that it was possible to engineer a multiplexed, activity-based detection platform based 
on QD emission.  
The results demonstrate that QD-based assays could be used for the activity-
dependent detection of p300 HAT, HER2 kinase and uPA protease. The format was 
amenable to screening of small-molecule inhibitors of p300, and by using an 
orthogonal coupling strategy it was possible to detect HER2 and uPA in a multiplexed 
assay. Some consideration was given to cases where it may not be possible to find a 
specifically-binding antibody. In particular for kinases, the specificity of anti-
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phosphotyrosine antibodies for their target is much better than that of anti-
phosphoserine or anti-phosphothreonine [41, 119].   
The p300 HAT detection system has high sensitivity, is simple to perform, requires 
low reagent volumes, and can report on enzyme inhibition. These aspects make the 
assay highly relevant for automated HTS of HAT inhibitors, as well as inhibitors of 
the antagonistic enzyme family, HDACs. In order to demonstrate the assay 
applicability for diagnostics, it would be important to determine whether the assay 
could distinguish between mutant forms of the enzyme with different activities. In 
addition, further work would be required to allow the assay to be used with clinical 
samples, considering confounding factors such as NP stability and non-specific 
binding of serum/cytosolic proteins. The multiplexed HER2/uPA detection assay 
addresses an engineering challenge and to the best of my knowledge, represents the 
first application of NPs in the simultaneous, activity-based detection of multiple 
enzyme biomarkers. This type of assay could find application in biomarker profiling 
assays, where a panel of biomarkers can give more accurate and reliable information 
than relying on a single marker alone. For drug development, it would be useful to test 
the effect of inhibitors not just on the target of interest, but also on the other enzymes 
that act on the target or are acted upon by the target. Turning this information into a 
single measurement, rather than aggregating an ensemble of measurements would 
provide useful information about side effects, or reveal particularly potent drugs that 
could disable entire pathways, rather than just individual enzymes. Finally, the 
multiplex assay could be used to provide temporal information about enzyme 
cascades, again in a single measurement, rather than an ensemble.   
By way of comparison with the state of the art, the LOD of the QD-based detection 
systems have been shown to be at least competitive with radiolabelling assays, 
without the associated issues of disposal or multiple washing steps to reduce 
background. The fluorescence-based DELFIA® and LANCE® assays utilise 
lanthanide chelates in order to generate high sensitivity. However, compared to the 
reagents used in the QD-based assays (including molecular dye-labelled antibodies), 
which are cheaper to prepare, the lanthanides also lack a little in flexibility due to 
their discrete emission spectra. In terms of multiplexing in mixed enzyme samples, 
mass spectrometry is the major method for resolving complex samples, but remains 
cumbersome and time-consuming to perform. Mass spectrometry can, however, 
identify enzymes in a sample of unknown composition, whereas the QD-based 
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multiplex approach described in this thesis presents a simple, complementary assay 
for profiling the activity of multiple enzymes of known identity. 
The technology described in this thesis represents a proof of concept for a generic and 
easily modifiable enzyme detection platform. In order to transfer this system from a 
laboratory-based process to a user product, two major improvements should be 
implemented. Firstly, the reagent preparation needs to be scaled up to meet the 
demands of a large HTS operation, or manufacture of kits in an integrated device 
form. The automation of assay procedures would also be of utility in HTS. In this 
regard, the US National Institutes of Health offer guidelines for assessing HTS assays 
[159]. Secondly, for diagnostic purposes, the tolerance of the assay to biological 
media should be thoroughly tested, and if necessary, steps to improve the surface 
coating of the QDs for improved stability should be taken. This could be approached 
via the use of amphiphilic polymer or peptide ligands. 
NP-based biomarker detection methods are emerging an alternative to traditional 
methods of detection. QDs offer numerous advantages over organic fluorophores for 
fluorescence-based analyte detection. In this thesis, I have shown how QDs can be 
used for a variety of sensing applications, and that the use of these NPs can offer new 
modalities not accessible in fluorophore-based methods. These include: enhanced 
sensitivity due to binding of multiple ligands on the QD surface; and multiplexed 
detection due to the excitation of different QD emission wavelengths using a single 
source. QDs have already begun to impact on medical imaging [3] and in the future 
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